retrieval,study_ref,microbe,bacteria.code,exposed.R,syndrome,first author(s),study year,study period,study type,country,n_exposed,n_nonexposed,los,review_marker,cost_year,cost_currency,measure,se.measure,avexp,lowexp,highexp,otherexp,avnon,lownon,highnon,othernon,p,minexp,maxexp,minnon,maxnon,pvalue_flag,notes,both_los_cost,unique_id_4both,FLAG_COMPLETE,FLAG_MONEY,FLAG_EXPOSED<NON
zhen_63,"Adams DJ, Eberly MD, Goudie A, Nylund CM. Rising vancomycin-resistant
Enterococcus infections in hospitalized children in the United States. Hosp
Pediatr. 2016;6:404–11.",Enterococcus,efa,vancomycin,INF,Adams,2016,"1997, 2000, 2003,2006, 2009, and 2012.",Retrospective ,USA,3356,39505704,1,DRI,,,mean,95ci,14.3,14.1,14.6,,12.2,12,12.4,,,,,,,,p<0.001,1,82,FALSE,FALSE,FALSE
zhen_63,"Adams DJ, Eberly MD, Goudie A, Nylund CM. Rising vancomycin-resistant
Enterococcus infections in hospitalized children in the United States. Hosp
Pediatr. 2016;6:404–11.",Enterococcus,efa,vancomycin,INF,Adams,2016,"1997, 2000, 2003,2006, 2009, and 2012.",Retrospective ,USA,3356,39505704,0,DRI,2015,USD,mean,95ci,51020,43463,59891,,42787,37797,48434,,0.004,,,,,,,1,82,FALSE,FALSE,FALSE
cassini_53,"Ahn JY, Song JE, Kim MH, et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea: A matched case-control study. American journal of infection control. 2014;42(6):621-625.",Escherichia coli,eco,carbapenems,INF,Ahn,2014,10/06 -12/10,Matched case-control,South Korea,57,114,1,AMR,,,mean,sd,26.6,,,37.9,13.1,,,41.3,,,,,,,matched on Site of infection,0,0,FALSE,FALSE,FALSE
zhen_44,"Anderson DJ, Kaye KS, Chen LF, Schmader KE, Choi Y, Sloane R, et al. Clinical
and financial outcomes due to methicillin resistant Staphylococcus aureus
surgical site infection: a multi-center matched outcomes study. PLoS One.
2009;4:e8305.",Staphylococcus aureus,sau,methicillin,SSI,Anderson,2009,01/1998-04/2003,Cohort,USA,150,128,1,AMR,,,excess,95ci,5.5,1.97,9.11,,,,,,,,,,,,,1,1,FALSE,FALSE,FALSE
zhen_44,"Anderson DJ, Kaye KS, Chen LF, Schmader KE, Choi Y, Sloane R, et al. Clinical
and financial outcomes due to methicillin resistant Staphylococcus aureus
surgical site infection: a multi-center matched outcomes study. PLoS One.
2009;4:e8305.",Staphylococcus aureus,sau,methicillin,SSI,Anderson,2009,01/1998-04/2003,Cohort,USA,150,128,0,AMR,2003,USD,excess,95ci,24113,4521,43704,,,,,,,,,,,,,1,1,FALSE,FALSE,FALSE
zhen_44,"Anderson DJ, Kaye KS, Chen LF, Schmader KE, Choi Y, Sloane R, et al. Clinical
and financial outcomes due to methicillin resistant Staphylococcus aureus
surgical site infection: a multi-center matched outcomes study. PLoS One.
2009;4:e8305.",Staphylococcus aureus,sau,methicillin,SSI,Anderson,2009,01/1998-04/2003,Cohort,USA,150,231,1,DRI,,,excess_median,IQR,23,19.7,26.3,,,,,,,,,,,,,1,73,FALSE,FALSE,FALSE
zhen_44,"Anderson DJ, Kaye KS, Chen LF, Schmader KE, Choi Y, Sloane R, et al. Clinical
and financial outcomes due to methicillin resistant Staphylococcus aureus
surgical site infection: a multi-center matched outcomes study. PLoS One.
2009;4:e8305.",Staphylococcus aureus,sau,methicillin,SSI,Anderson,2009,01/1998-04/2003,Cohort,USA,150,231,0,DRI,2003,USD,excess,95ci,61681,23352,100011,,,,,,,,,,,,,1,73,FALSE,FALSE,FALSE
cassini_63,"Apisarnthanarak A, Kiratisin P, Mundy LM. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infection control and hospital epidemiology. Jul 2008;29(7):671-674.",Enterobacteriaceae,ent,ESBL,BSI,Apisarnthanarak,2008,07/03-12/07,Retrospective case-control,Thailand,36,108,1,AMR,,,median,range,8,1,43,,6,3,15,,,,,,,,"updated number of exposed from cassini to that presented in paper, total length of stay, P<0.001",1,98,FALSE,FALSE,FALSE
founou_57,"Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Predictors of mortality
among patients with community-onset infection due to extended-spectrum beta-lactamase-producing
Escherichia coli in Thailand. Infect Control Hosp Epidemiol. 2008; 29(1):80±2. https://doi.org/10.1086/
524321 PMID: 18171194",Enterobacteriaceae,ent,ESBL,BSI,Apisarnthanarak,2008,07/2003-12/2007,Case control,Thailand,36,108,0,AMR,2007,USD,median,range,615,43,3173,,214,53,1861,,,,,,,,"cost after infection, P<0.001",1,98,FALSE,FALSE,FALSE
founou_56,"Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Risk factors for and outcomes
of healthcare-associated infection due to extended-spectrum beta-lactamase-producing Escherichia
coli or Klebsiella pneumoniae in Thailand. Infect Control Hosp Epidemiol. 2007; 28(7):873±6.
https://doi.org/10.1086/518725 PMID: 17564993",Enterobacteriaceae,ent,ESBL,INF,Apisarnthanarak,2007,07/2003-06/2004,Prospective case Adults,Thailand,74,74,0,AMR,2004,USD,median,range,1935,42,4224,,1122,30,3773,,,,,,,,"p<0.05, gives count breakdown of source, healthcare associated infection",1,2,FALSE,FALSE,FALSE
founou_56,"Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Risk factors for and outcomes
of healthcare-associated infection due to extended-spectrum beta-lactamase-producing Escherichia
coli or Klebsiella pneumoniae in Thailand. Infect Control Hosp Epidemiol. 2007; 28(7):873±6.
https://doi.org/10.1086/518725 PMID: 17564993",Enterobacteriaceae,ent,ESBL,INF,Apisarnthanarak,2007,07/2003-06/2004,Prospective case Adults,Thailand,74,74,1,AMR,,,median,range,22.5,1,48,,17.5,1,37,,,,,,,,"p<0.05, gives count breakdown of source, healthcare associated infection",1,2,FALSE,FALSE,FALSE
founou_56,"Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Risk factors for and outcomes
of healthcare-associated infection due to extended-spectrum beta-lactamase-producing Escherichia
coli or Klebsiella pneumoniae in Thailand. Infect Control Hosp Epidemiol. 2007; 28(7):873±6.
https://doi.org/10.1086/518725 PMID: 17564993",Enterobacteriaceae,ent,ESBL,INF,Apisarnthanarak,2007,07/2003-06/2004,Prospective case Adults,Thailand,74,74,0,DRI,2004,USD,median,range,1935,42,4224,,545,42,2172,,,,,,,,"p<0.05, gives count breakdown of source, healthcare associated infection",1,99,FALSE,FALSE,FALSE
founou_56,"Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Risk factors for and outcomes
of healthcare-associated infection due to extended-spectrum beta-lactamase-producing Escherichia
coli or Klebsiella pneumoniae in Thailand. Infect Control Hosp Epidemiol. 2007; 28(7):873±6.
https://doi.org/10.1086/518725 PMID: 17564993",Enterobacteriaceae,ent,ESBL,INF,Apisarnthanarak,2007,07/2003-06/2004,Prospective case Adults,Thailand,74,74,1,DRI,,,median,range,22.5,1,48,,11.5,1,18,,,,,,,,"p<0.05, gives count breakdown of source, healthcare associated infection",1,99,FALSE,FALSE,FALSE
zhen_84,"Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM.
Clinical and molecular epidemiology of community-onset, extendedspectrum
beta-lactamase-producing Escherichia coli infections in Thailand: a
case-case-control study. Am J Infect Control. 2007;35:606–12.",Escherichia coli,eco,ESBL,INF,Apisarnthanarak,2007,07/2003-06/2004,Retrospective cohort,Thailand,46,46,1,AMR,,,median,range,8,1,43,,6,3,14,,,,,,,,"gives count breakdown of source, community associated infection",1,60,FALSE,FALSE,FALSE
zhen_84,"Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM.
Clinical and molecular epidemiology of community-onset, extendedspectrum
beta-lactamase-producing Escherichia coli infections in Thailand: a
case-case-control study. Am J Infect Control. 2007;35:606–12.",Escherichia coli,eco,ESBL,INF,Apisarnthanarak,2007,07/2003-06/2004,Retrospective cohort,Thailand,46,46,0,AMR,2004,THB,median,range,21120,1720,126920,,4800,1160,34000,,,,,,,,"US dollars at an exchange rate of 40 baht per 1 US dollar conversion used in paper, gives count breakdown of source, community associated infection",1,60,FALSE,FALSE,FALSE
zhen_84,"Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM.
Clinical and molecular epidemiology of community-onset, extendedspectrum
beta-lactamase-producing Escherichia coli infections in Thailand: a
case-case-control study. Am J Infect Control. 2007;35:606–12.",Escherichia coli,eco,ESBL,INF,Apisarnthanarak,2007,07/2003-06/2004,Retrospective cohort,Thailand,46,138,1,DRI,,,median,range,8,1,43,,5,3,13,,,,,,,,"gives count breakdown of source, community associated infection",1,90,FALSE,FALSE,FALSE
zhen_84,"Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM.
Clinical and molecular epidemiology of community-onset, extendedspectrum
beta-lactamase-producing Escherichia coli infections in Thailand: a
case-case-control study. Am J Infect Control. 2007;35:606–12.",Escherichia coli,eco,ESBL,INF,Apisarnthanarak,2007,07/2003-06/2004,Retrospective cohort,Thailand,46,138,0,DRI,2004,THB,median,range,21120,1720,126920,,4320,920,31600,,,,,,,,"US dollars at an exchange rate of 40 baht per 1 US dollar conversion used in paper, gives count breakdown of source, community associated infection",1,90,FALSE,FALSE,FALSE
naylor_151,"Apostolopoulou E, Zikos D. Clinical outcomes and economic variables in critically ill patients with bloodstream infections. 2014;8. ",Gram-negative,gn,carbapenems,BSI,Apostolopoulou,2014,01/10-12/10,Prospective observational,Greece,na,na,1,AMR,,,median,95ci,14,9,19,,10,7.5,12.5,,,,,,,,"compared to non-infected, ICU, P<0.001",0,0,FALSE,FALSE,FALSE
naylor_151,"Apostolopoulou E, Zikos D. Clinical outcomes and economic variables in critically ill patients with bloodstream infections. 2014;8. ",Gram-negative,gn,carbapenems,BSI,Apostolopoulou,2014,01/10-12/10,Prospective observational,Greece,na,na,1,DRI,,,excess_median,95ci,14,9,19,,,,,,,,,,,,"vs median for non-infected as baseline, ICU, P<0.001",1,99,FALSE,FALSE,FALSE
cassini_91,"Arnan M, Gudiol C, Calatayud L, et al. Risk factors for, and clinical relevance of, faecal extended-spectrum beta-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. Mar 2011;30(3):355-360.",Escherichia coli,eco,3g cephalosporins,COL/INF,Arnan,2011,05/06-12/07,Prospective cohort study,Spain,63,154,1,DRI,,,mean,sd,30.15,,,13.7,29.05,,,12.11,,,,,,0.6,"neutropenic cancer patients, a proportion had infections",0,0,FALSE,FALSE,FALSE
cassini_17,"Aydemir H, Celebi G, Piskin N, et al. Mortality attributable to carbapenem-resistant nosocomial Acinetobacter baumannii infections in a Turkish university hospital. Japanese journal of infectious diseases. 2012;65(1):66-71.",Acinetobacter baumannii,aba,carbapenems,INF,Aydemir,2012,01/05-12/06,Retrospective case-control,Turkey,110,55,1,AMR,,,mean,sd,22.4,,,29.1,16.5,,,17.1,0.671,,,,,,"after microbe isolation, includes % pnuemonia vs non-pneumonia infections",0,0,FALSE,FALSE,FALSE
founou_30,"Baran G, Erbay A, Bodur H, Onguru P, Akinci E, Balaban N, et al. Risk factors for nosocomial imipenem-
resistant Acinetobacter baumannii infections. International journal of infectious diseases: IJID: official
publication of the International Society for Infectious Diseases. 2008; 12(1):16±21.",Acinetobacter baumannii,aba,imipenem,INF,Baran,2008,01/2004-12/2004,Prospective case,Turkey,66,57,1,AMR,,,mean,sd,20.8,,,13.6,15.4,,,9.4,0.014,,,,,,"Nosocomial ICU and A. baumannii , Adults>16",0,0,FALSE,FALSE,FALSE
naylor_18,"Barnett AG, Page K, Campbell M, Martin E, Rashleigh-Rolls R, Halton K, et al. The increased risks of death and extra lengths of hospital and ICU stay from hospital-acquired bloodstream infections: a case-control study. BMJ Open. 2013;3:e003587. ",Staphylococcus aureus,sau,methicillin,BSI,Barnett,2013,01/05-32/10,Cohort,Australia,189,555,1,AMR,,,mean,95ci,12.8,6.2,26.1,,11,6.4,14.9,,,,,,,,"matched on had the same first letter in the principal diagnosis code (using ICD-10 coding), were of a similar age (within 10 years), were at the same hospital, and were infectionfree at the time of the case’s infection, and being discharged alive",0,0,FALSE,FALSE,FALSE
naylor_18,"Barnett AG, Page K, Campbell M, Martin E, Rashleigh-Rolls R, Halton K, et al. The increased risks of death and extra lengths of hospital and ICU stay from hospital-acquired bloodstream infections: a case-control study. BMJ Open. 2013;3:e003587. ",Staphylococcus aureus,sau,methicillin,BSI,Barnett,2013,01/05-32/10,Cohort,Australia,189,555,1,AMR,,,mean,95ci,1.6,-12.6,12.6,,2.7,-2.6,9.7,,,,,,,,"matched on had the same first letter in the principal diagnosis code (using ICD-10 coding), were of a similar age (within 10 years), were at the same hospital, and were infectionfree at the time of the case’s infection, and dying within hospital",0,0,FALSE,FALSE,TRUE
zhen_38,"Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost
between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus
bloodstream infection? Infect Control Hosp Epidemiol. 2009;30:453–60.",Staphylococcus aureus,sau,methicillin,BSI,Ben-David,2009,01/2000–08/2003,Case-control,USA,53,53,1,AMR,,,median,IQR,16,11,22,,12,9,23,,0.3,,,,,,General ward,1,56,FALSE,FALSE,FALSE
zhen_38,"Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost
between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus
bloodstream infection? Infect Control Hosp Epidemiol. 2009;30:453–60.",Staphylococcus aureus,sau,methicillin,BSI,Ben-David,2009,01/2000–08/2003,Case-control,USA,53,53,0,AMR,2003,USD,median,IQR,23690,13545,43375,,18152,11091,33202,,0.3,,,,,,General ward,1,56,FALSE,FALSE,FALSE
cassini_167,"Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med. Oct 28 2002;162(19):2229-2235.",Staphylococcus aureus,sau,methicillin,BSI,Blot,2002,01/92-12/98,Retrospective cohort study,Belgium,47,38,1,AMR,,,mean,sd,37,,,28.7,18,,,16.2,,,,,,,"APACHE II
score,
diagnostic
category",0,0,FALSE,FALSE,FALSE
naylor_24,"Branch-Elliman W, Lee GM, Golen TH, Gold HS, Baldini LM, Wright SB. Health and Economic Burden of Post-Partum Staphylococcus aureus Breast Abscess. PLoS ONE. 2013;8:1–7.",Staphylococcus aureus,sau,methicillin,SSTI,Branch-Elliman,2013,10/2003–9/2010,Cohort,USA,30,24,0,AMR,2012,USD,excess,95ci,507,-818,1842,,,,,,0.45,,,,,,Post-partum women,0,0,FALSE,FALSE,FALSE
cassini_24,"Brooklyn Antibiotic Resistance Task Force. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infection control and hospital epidemiology. Feb 2002;23(2):106-108.",Acinetobacter baumannii,aba,carbapenems,INF,BARTF,2002,3 months 1999,Matched case-control,USA,10,10,1,AMR,,,median,pvalue,31.5,,,,13,,,,0.02,,,,,,"after infection, matched on age, site of infection, underlying disease, opeartive procedure, type of infection. % breakdown of source",0,0,FALSE,FALSE,FALSE
cassini_24,"Brooklyn Antibiotic Resistance Task Force. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infection control and hospital epidemiology. Feb 2002;23(2):106-108.",Staphylococcus aureus,sau,methicillin,INF,BARTF,2002,3 months 1999,Matched case-control,USA,14,14,1,AMR,,,median,pvalue,18,,,,14,,,,0.04,,,,,,"after infection, matched on age, site of infection, underlying disease, opeartive procedure, type of infection. % breakdown of source",0,0,FALSE,FALSE,FALSE
cassini_24,"Brooklyn Antibiotic Resistance Task Force. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infection control and hospital epidemiology. Feb 2002;23(2):106-108.",Pseudomonas aeruginosa,pae,carbapenems,INF,BARTF,2002,3 months 1999,Matched case-control,USA,10,10,1,AMR,,,median,pvalue,33.5,,,,20,,,,0.002,,,,,,"after infection, matched on age, site of infection, underlying disease, opeartive procedure, type of infection. % breakdown of source",0,0,FALSE,FALSE,FALSE
cassini_24,"Brooklyn Antibiotic Resistance Task Force. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infection control and hospital epidemiology. Feb 2002;23(2):106-108.",Klebsiella pneumoniae,kpn,ESBL,INF,BARTF,2002,3 months 1999,Matched case-control,USA,9,9,1,AMR,,,median,pvalue,29,,,,11,,,,0.03,,,,,,"after infection, matched on age, site of infection, underlying disease, opeartive procedure, type of infection. % breakdown of source",0,0,FALSE,FALSE,FALSE
cassini_189,"Burke RE, Halpern MS, Baron EJ, Gutierrez K. Pediatric and neonatal Staphylococcus aureus bacteremia: epidemiology, risk factors, and outcome. Infection control and hospital epidemiology. Jul 2009;30(7):636-644.",Staphylococcus aureus,sau,methicillin,BSI,Burke,2009,2001-2006,Retrospective study,USA,29,121,1,AMR,,,median,IQR,38,16,73,,16,7,42,,0.003,,,,,,"age, note paediatric patients",0,0,FALSE,FALSE,FALSE
zhen_58,"Butler AM, Olsen MA, Merz LR, Guth RM, Woeltje KF, Camins BC, et al.
Attributable costs of Enterococcal bloodstream infections in a nonsurgical
hospital cohort. Infect Control Hosp Epidemiol. 2010;31:28–35.",Enterococcus,efa,vancomycin,BSI,Butler,2010,2002-2003,Cohort,USA,94,182,1,AMR,,,mean,95ci,2.3,1.8,2.8,,1.2,0.9,1.5,,,,,,,,using GLS regression,1,28,FALSE,FALSE,FALSE
zhen_58,"Butler AM, Olsen MA, Merz LR, Guth RM, Woeltje KF, Camins BC, et al.
Attributable costs of Enterococcal bloodstream infections in a nonsurgical
hospital cohort. Infect Control Hosp Epidemiol. 2010;31:28–35.",Enterococcus,efa,vancomycin,BSI,Butler,2010,2002-2003,Cohort,USA,94,182,0,AMR,2007,USD,mean,95ci,4479,3500,5732,,2250,1758,2880,,,,,,,,using GLS regression,1,28,FALSE,FALSE,FALSE
zhen_58,"Butler AM, Olsen MA, Merz LR, Guth RM, Woeltje KF, Camins BC, et al.
Attributable costs of Enterococcal bloodstream infections in a nonsurgical
hospital cohort. Infect Control Hosp Epidemiol. 2010;31:28–35.",Enterococcus,efa,vancomycin,BSI,Butler,2010,2002-2003,Cohort,USA,94,182,1,AMR,,,mean,95ci,2.2,1.7,2.7,,1.1,0.9,1.4,,,,,,,,GLS regression model with propensity weighting,1,29,FALSE,FALSE,FALSE
zhen_58,"Butler AM, Olsen MA, Merz LR, Guth RM, Woeltje KF, Camins BC, et al.
Attributable costs of Enterococcal bloodstream infections in a nonsurgical
hospital cohort. Infect Control Hosp Epidemiol. 2010;31:28–35.",Enterococcus,efa,vancomycin,BSI,Butler,2010,2002-2003,Cohort,USA,94,182,0,AMR,2007,USD,mean,95ci,4036,3170,5140,,2023,1588,2575,,,,,,,,GLS regression model with propensity weighting,1,29,FALSE,FALSE,FALSE
cassini_119,"Candevir Ulu A, Kurtaran B, Inal AS, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infection: a serious threat in ICUs. Medical science monitor : international medical journal of experimental and clinical research. 2015;21:219-224.",Klebsiella pneumoniae,kpn,carbapenems,INF,Candevir ulu,2014,01/12-12/12,Retrospective cohort study,Turkey,47,51,1,AMR,,,mean,sd,37.3,,,50.838,29.94,,,94.558,0.026,1,280,3,682,,"ICU, gives count breakdown of source",0,0,FALSE,FALSE,FALSE
zhen_66,"Carmeli Y, Eliopoulos G,Mozaffari E, Samore M. Health and economic outcomes
of vancomycin-resistant enterococci. Arch Intern Med. 2002;162:2223–8.",Enterococcus,efa,vancomycin,UTI,Carmeli,2002,10/93-12/97,Retrospective ,USA,72,647,0,DRI,1997,USD,excess,pvalue,6665,,,,,,,,0.02,,,,,,sample size derived using percentages given ,0,0,FALSE,FALSE,FALSE
zhen_66,"Carmeli Y, Eliopoulos G,Mozaffari E, Samore M. Health and economic outcomes
of vancomycin-resistant enterococci. Arch Intern Med. 2002;162:2223–8.",Enterococcus,efa,vancomycin,IAI,Carmeli,2002,10/93-12/97,Retrospective ,USA,40,647,1,DRI,,,excess,pvalue,2.6,,,,,,,,0.06,,,,,,sample size derived using percentages given ,1,84,FALSE,FALSE,FALSE
zhen_66,"Carmeli Y, Eliopoulos G,Mozaffari E, Samore M. Health and economic outcomes
of vancomycin-resistant enterococci. Arch Intern Med. 2002;162:2223–8.",Enterococcus,efa,vancomycin,IAI,Carmeli,2002,10/93-12/97,Retrospective ,USA,40,647,0,DRI,1997,USD,excess,pvalue,22896,,,,,,,,0.01,,,,,,sample size derived using percentages given ,1,84,FALSE,FALSE,FALSE
zhen_66,"Carmeli Y, Eliopoulos G,Mozaffari E, Samore M. Health and economic outcomes
of vancomycin-resistant enterococci. Arch Intern Med. 2002;162:2223–8.",Enterococcus,efa,vancomycin,BSI,Carmeli,2002,10/93-12/97,Retrospective ,USA,21,647,1,DRI,,,excess,pvalue,15,,,,,,,,0.07,,,,,,sample size derived using percentages given ,1,86,FALSE,FALSE,FALSE
zhen_66,"Carmeli Y, Eliopoulos G,Mozaffari E, Samore M. Health and economic outcomes
of vancomycin-resistant enterococci. Arch Intern Med. 2002;162:2223–8.",Enterococcus,efa,vancomycin,BSI,Carmeli,2002,10/93-12/97,Retrospective ,USA,21,647,0,DRI,1997,USD,excess,pvalue,13537,,,,,,,,0.3,,,,,,sample size derived using percentages given ,1,86,FALSE,FALSE,FALSE
naylor_26,"Casapao  a. M, Leonard SN, Davis SL, Lodise TP, Patel N, Goff D a., et al. Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection. Antimicrobial Agents and Chemotherapy. 2013;57:4252–9. ",Staphylococcus aureus,sau,vancomycin,BSI,Casapao,2013,01/04 - 08/12,Cohort,USA,61,61,1,AMR,,,median,IQR,22,12,39,,13,9,28,,0.021,,,,,,"length of stay after positive blood culture, all adults",0,0,FALSE,FALSE,FALSE
cassini_12,"Chang HC, Chen YC, Lin MC, et al. Mortality risk factors in patients with Acinetobacter baumannii ventilator: associated pneumonia. Journal of the Formosan Medical Association = Taiwan yi zhi. Sep 2011;110(9):564-571.",Acinetobacter baumannii,aba,carbapenems,RTI,Chang,2011,01/05-12/07,Retrospective observational,Taiwan,93,87,1,AMR,,,median,sd,23.1,,,24.3,26.7,,,24.3,0.331,,,,,,critically ill patients,0,0,FALSE,FALSE,TRUE
cassini_51,"Chang HJ, Hsu PC, Yang CC, et al. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: A matched case-control study. Journal of Microbiology, Immunology and Infection. 2011;44(2):125-130",Escherichia coli,eco,carbapenems,BSI,Chang,2011,01/06-12/08,Matched case-control,Taiwan,17,34,1,AMR,,,mean,sd,68.4,,,56.4,35.8,,,34.5,,,,,,,"matched on gender, age, year of hosp, length stay before isolation",0,0,FALSE,FALSE,FALSE
cassini_328,"Cheah AL, Spelman T, Liew D, et al. Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Apr 2013;19(4):E181-189",Enterococcus faecium,efa,vancomycin,BSI,Cheah,2013,2002 - 2010,Retrospective matched cohort,Australia,116,116,1,AMR,,,excess,95ci,4.89,0.56,11.52,,,,,,,,,,,,matched on date and unit of admission,1,52,FALSE,FALSE,FALSE
cassini_328,"Cheah AL, Spelman T, Liew D, et al. Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Apr 2013;19(4):E181-189",Enterococcus faecium,efa,vancomycin,BSI,Cheah,2013,2002 - 2010,Retrospective matched cohort,Australia,116,116,0,AMR,2011,AUD,excess,95ci,28872,734,70667,,,,,,,,,,,,matched on date and unit of admission,1,52,FALSE,FALSE,FALSE
founou_48,"Chen R, Yan ZQ, Feng D, Luo YP, Wang LL, Shen DX. Nosocomial bloodstream infection in patients
caused by Staphylococcus aureus: drug susceptibility, outcome, and risk factors for hospital mortality.
Chin Med J (Engl). 2012; 125(2):226±9.",Staphylococcus aureus,sau,methicillin,BSI,Chen,2012,01/2006-05/2011,Retrospective > 1 year old,China,75,43,1,AMR,,,mean,sd,55.3,,,44.4,38.7,,,31.3,0.0328,,,,,,Various,0,0,FALSE,FALSE,FALSE
zhen_91,"Chen Z, Xu Z, Wu H, Chen L, Gao S, Chen Y. The impact of carbapenemresistant
Pseudomonas aeruginosa on clinical and economic outcomes in a
Chinese tertiary care hospital: a propensity score-matched analysis. Am J
Infect Control. 2018;47:677-82.",Pseudomonas aeruginosa,pae,carbapenems,COL/INF,Chen,2018,01/2014-03/2018,Retrospective matched cohort,China,270,270,1,AMR,,,median,IQR,18.5,8,30,,14,7,28,,0.29,,,,,,"after infection, 84% of CR and 93% of CS had infections",1,36,FALSE,FALSE,FALSE
zhen_91,"Chen Z, Xu Z, Wu H, Chen L, Gao S, Chen Y. The impact of carbapenemresistant
Pseudomonas aeruginosa on clinical and economic outcomes in a
Chinese tertiary care hospital: a propensity score-matched analysis. Am J
Infect Control. 2018;47:677-82.",Pseudomonas aeruginosa,pae,carbapenems,COL/INF,Chen,2018,01/2014-03/2018,Retrospective matched cohort,China,270,270,0,AMR,2018,USD,median,IQR,6082,3333.1,12662.6,,4954.2,2755.9,162.1,,0.15,,,,,,"total hospital stay cost, 84% of CR and 93% of CS had infections",1,36,FALSE,FALSE,FALSE
zhen_87,"Cornejo-Juarez P, Suarez-Cuenca JA, Volkow-Fernandez P, Silva-Sanchez J,
Barrios-Camacho H, Najera-Leon E, et al. Fecal ESBL Escherichia coli carriage
as a risk factor for bacteremia in patients with hematological malignancies.
Support Care Cancer. 2016;24:253–9",Escherichia coli,eco,ESBL,COL/INF,Cornejo-Juarez,2016,10/2012-01/2014,Prospective cohort study,Mexico,63,63,1,AMR,,,mean,sd,64,,,39,48,,,32,,,,,,0.01,"cancer patients, patients with hematologic malignancies (HM) and severe neutropenia, a proportion went on to develop BSI",1,37,FALSE,FALSE,FALSE
zhen_87,"Cornejo-Juarez P, Suarez-Cuenca JA, Volkow-Fernandez P, Silva-Sanchez J,
Barrios-Camacho H, Najera-Leon E, et al. Fecal ESBL Escherichia coli carriage
as a risk factor for bacteremia in patients with hematological malignancies.
Support Care Cancer. 2016;24:253–9",Escherichia coli,eco,ESBL,COL/INF,Cornejo-Juarez,2016,10/2012-01/2014,Prospective cohort study,Mexico,63,63,0,AMR,2014,USD,mean,sd,6528,,,4348,4722,,,3174,,,,,,0.01,"cancer patients, patients with hematologic malignancies (HM) and severe neutropenia, a proportion went on to develop BSI",1,37,FALSE,FALSE,FALSE
zhen_53,"Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact
of methicillin resistance in Staphylococcus aureus bacteremia on patient
outcomes: mortality, length of stay, and hospital charges. Infect Control
Hosp Epidemiol. 2005;26:166–74",Staphylococcus aureus,sau,methicillin,BSI,Cosgrove,2005,07/1997-06/2000,Cohort,USA,96,252,1,AMR,,,median,pvalue,9,,,,7,,,,0.045,,,,,,,1,26,FALSE,FALSE,FALSE
zhen_53,"Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact
of methicillin resistance in Staphylococcus aureus bacteremia on patient
outcomes: mortality, length of stay, and hospital charges. Infect Control
Hosp Epidemiol. 2005;26:166–74",Staphylococcus aureus,sau,methicillin,BSI,Cosgrove,2005,07/1997-06/2000,Cohort,USA,96,252,0,AMR,2015,USD,excess_median,IQR,5502,3058,10630,,,,,,0.008,,,,,,hospital cost after culture,1,26,FALSE,FALSE,FALSE
cassini_253,"Dantas RC, Ferreira ML, Gontijo-Filho PP, Ribas RM. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome. Journal of medical microbiology. Dec 2014;63(Pt 12):1679-1687.",Pseudomonas aeruginosa,pae,carbapenems,BSI,Dantas,2014,05/09-08/11,Retrospective study,Brazil,55,65,1,AMR,,,mean,range,48,4,205,,41,3,378,,,,,,,,,0,0,FALSE,FALSE,FALSE
naylor_48,"De Jager P, Chirwa T, Naidoo S, Perovic O, Thomas J. Nosocomial outbreak of New Delhi metallo-Beta-lactamase-1-producing Gram-negative bacteria in South Africa: A case-control study. PLoS ONE. 2015;10:1–12. ",Gram-negative,gn,MBL,INF,De Jager,2015,11/2012-11/2013,Matched case-control,South Africa,38,68,1,DRI,,,mean,sd,44,,,28.2,13.3,,,9.5,,,,,,,p<0.0001,0,0,FALSE,FALSE,FALSE
cassini_193,"de Kraker ME, Wolkewitz M, Davey PG, et al. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrobial agents and chemotherapy. Apr 2011;55(4):1598-1605.",Staphylococcus aureus,sau,methicillin,BSI,De Kraker,2011,07/07-06/08,Prospective parallel matched double cohort,Europe,248,618,1,AMR,,,excess,95ci,0.6,-3.7,5.3,,,,,,,,,,,,"note compared to non-infected first to then estimate excess values, sample numbers are total exposed and non-exposed, some may/were dropped for the multivariate analyses extracted for the results in this table",0,0,FALSE,FALSE,FALSE
cassini_193,"de Kraker ME, Wolkewitz M, Davey PG, et al. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrobial agents and chemotherapy. Apr 2011;55(4):1598-1605.",Staphylococcus aureus,sau,methicillin,BSI,De Kraker,2011,07/07-06/08,Prospective parallel matched double cohort,Europe,248,453,1,DRI,,,excess,95ci,9.2,5.2,13.5,,,,,,,,,,,,"sample numbers are total exposed and non-exposed, some may/were dropped for the multivariate analyses extracted for the results in this table",0,0,FALSE,FALSE,FALSE
cassini_61,"de Kraker MEA, Wolkewitz M, Davey PG, et al. Burden of antimicrobial resistance in European hospitals: Excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. Journal of Antimicrobial Chemotherapy. 2011;66(2):398-407.",Escherichia coli,eco,3g cephalosporins,BSI,De Kraker,2011,07/07-06/08,Prospective parallel matched double cohort,Europe,111,1110,1,AMR,,,excess,95ci,5,0.4,10.2,,,,,,,,,,,,"note compared to non-infected first to then estimate excess values, sample numbers are total exposed and non-exposed, some may/were dropped for the multivariate analyses extracted for the results in this table",0,0,FALSE,FALSE,FALSE
cassini_61,"de Kraker MEA, Wolkewitz M, Davey PG, et al. Burden of antimicrobial resistance in European hospitals: Excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. Journal of Antimicrobial Chemotherapy. 2011;66(2):398-407.",Escherichia coli,eco,3g cephalosporins,BSI,De Kraker,2011,07/07-06/08,Prospective parallel matched double cohort,Europe,111,204,1,DRI,,,excess,95ci,7.9,3.5,13,,,,,,,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_115,"Debby BD, Ganor O, Yasmin M, et al. Epidemiology of carbapenem resistant Klebsiella pneumoniae colonization in an intensive care unit. European journal of clinical microbiology & infectious diseases : official",Klebsiella pneumoniae,kpn,carbapenems,COL/INF,Debby,2012,05/07-04/ 08,Prospective cohort study,Israel,48,132,1,DRI,,,mean,sd,56.7,,,41.2,44.3,,,39.8,0.07,,,,,,"hospital acquired infections, different from cassini et al extractions as theirs was before ICU admission ",0,0,FALSE,FALSE,FALSE
cassini_75,"Denis B, Lafaurie M, Donay JL, et al. Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Oct 2015;39:1-6.",Escherichia coli,eco,3g cephalosporins,BSI,Denis,2015,01/05-12/09,Retrospective study,France,41,41,1,AMR,,,median,range,15,10,21,,11,7,17,,0.88,,,,,,matched on date of isolation,0,0,FALSE,FALSE,FALSE
cassini_329,"DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis. Feb 15 2005;191(4):588-595.",Enterococcus faecium,efa,vancomycin,BSI,DiazGranado,2005,1994-2001,Retrospective cohort study,USA,22,61,1,AMR,,,median,range,42,24,75,,31,2,72,,0.0084,,,,,,matched on patients with neutropenia,0,0,FALSE,FALSE,FALSE
cassini_214,"Dolapo O, Dhanireddy R, Talati AJ. Trends of Staphylococcus aureus bloodstream infections in a neonatal intensive care unit from 2000-2009. BMC pediatrics. May 09 2014;14:121.",Staphylococcus aureus,sau,methicillin,BSI,Dolapo,2014,2000-2003,Retrospective study,USA,10,31,1,AMR,,,mean,sd,80.6,,,42.4,87.4,,,40.6,,,,,,,"NICU, period A",0,0,FALSE,FALSE,TRUE
cassini_214,"Dolapo O, Dhanireddy R, Talati AJ. Trends of Staphylococcus aureus bloodstream infections in a neonatal intensive care unit from 2000-2009. BMC pediatrics. May 09 2014;14:121.",Staphylococcus aureus,sau,methicillin,BSI,Dolapo,2014,2004-2009,Retrospective study,USA,64,51,1,AMR,,,mean,sd,53.6,,,36.6,55.7,,,30.2,,,,,,,"NICU, period B",0,0,FALSE,FALSE,TRUE
cassini_262,"Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infection control and hospital epidemiology. Aug 2009;30(8):746-752.",Pseudomonas aeruginosa,pae,meropenem,INF,Eagye,2009,02/06-10/06,Case-control-control study,USA,58,125,1,AMR,,,median,IQR,30,15,70,,16,6,33,,,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_262,"Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infection control and hospital epidemiology. Aug 2009;30(8):746-752.",Pseudomonas aeruginosa,pae,meropenem,INF,Eagye,2009,02/06-10/06,Case-control-control study,USA,58,57,1,DRI,,,median,IQR,30,15,70,,10,6,17,,,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_337,"Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. May 1995;20(5):1126-1133.",Enterococcus faecalis and faecium,efa,vancomycin,BSI,Edmond,1995,1993,Pairwise matched case-control,USA,11,22,1,DRI,,,mean,sd,74.75,,,46.27,47.26,,,37.59,,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_301,"Einarsson S, Kristjansson M, Kristinsson KG, Kjartansson G, Jonsson S. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: a case-control study. Scandinavian journal of infectious diseases. 1998;30(3):253-256.",Streptococcus pneumoniae,spn,penicillins,RTI,Einarsson,1998,1988-1994,Retrospective case-control study,Iceland,36,36,1,AMR,,,mean,pvalue,26.8,,,,11.5,,,,0.001,,,,,,,0,0,FALSE,FALSE,FALSE
zhen_43,"Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL,
et al. Adverse clinical and economic outcomes attributable to methicillin
resistance among patients with Staphylococcus aureus surgical site
infection. Clin Infect Dis. 2003;36:592–8.",Staphylococcus aureus,sau,methicillin,SSI,Engemann,2003,01/1994-11/2000,Cohort,USA,121,165,1,AMR,,,median,IQR,23,12,38,,14,7,25,,,,,,,,p<.001,1,35,FALSE,FALSE,FALSE
zhen_43,"Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL,
et al. Adverse clinical and economic outcomes attributable to methicillin
resistance among patients with Staphylococcus aureus surgical site
infection. Clin Infect Dis. 2003;36:592–8.",Staphylococcus aureus,sau,methicillin,SSI,Engemann,2003,01/1994-11/2000,Cohort,USA,121,165,0,AMR,2003,USD,median,IQR,92363,40198,136479,,52791,29074,91805,,,,,,,,p<.001,1,35,FALSE,FALSE,FALSE
zhen_43,"Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL,
et al. Adverse clinical and economic outcomes attributable to methicillin
resistance among patients with Staphylococcus aureus surgical site
infection. Clin Infect Dis. 2003;36:592–8.",Staphylococcus,sau,methicillin,SSI,Engemann,2003,01/1994-11/2000,Cohort,USA,121,193,1,DRI,,,median,IQR,23,12,28,,5,3,8,,,,,,,,p<0.001,1,72,FALSE,FALSE,FALSE
zhen_43,"Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL,
et al. Adverse clinical and economic outcomes attributable to methicillin
resistance among patients with Staphylococcus aureus surgical site
infection. Clin Infect Dis. 2003;36:592–8.",Staphylococcus,sau,methicillin,SSI,Engemann,2003,01/1994-11/2000,Cohort,USA,121,193,0,DRI,2003,USD,median,IQR,92363,40198,136479,,29455,15637,41764,,,,,,,,p<0.001,1,72,FALSE,FALSE,FALSE
zhen_57,"Engler-Huesch S, Heister T, Mutters NT, Wolff J, Kaier K. In-hospital costs of
community-acquired colonization with multidrug-resistant organisms at a
German teaching hospital. BMC Health Serv Res. 2018;18:737.",Staphylococcus aureus,sau,methicillin,COL,Engler-Huesch,2018,01/2011-12/2014,Matched case-cohort design,Germany,453,7917,0,DRI,2014,EUR,mean,sd,5988.53,,,6061.12,5504.37,,,8125.41,,,,,,,,1,78,FALSE,FALSE,FALSE
zhen_57,"Engler-Huesch S, Heister T, Mutters NT, Wolff J, Kaier K. In-hospital costs of
community-acquired colonization with multidrug-resistant organisms at a
German teaching hospital. BMC Health Serv Res. 2018;18:737.",Staphylococcus aureus,sau,methicillin,COL,Engler-Huesch,2018,01/2011-12/2014,Matched case-cohort design,Germany,453,7917,1,DRI,,,mean,sd,10.02,,,9.21,8.93,,,9.21,,,,,,,,1,78,FALSE,FALSE,FALSE
zhen_57,"Engler-Huesch S, Heister T, Mutters NT, Wolff J, Kaier K. In-hospital costs of
community-acquired colonization with multidrug-resistant organisms at a
German teaching hospital. BMC Health Serv Res. 2018;18:737.",Enterococcus,efa,vancomycin,COL,Engler-Huesch,2018,01/2011-12/2014,Matched case-cohort design,Germany,1004,7917,0,DRI,2014,EUR,mean,sd,7390.47,,,8723.73,5504.37,,,8125.41,,,,,,,,1,79,FALSE,FALSE,FALSE
zhen_57,"Engler-Huesch S, Heister T, Mutters NT, Wolff J, Kaier K. In-hospital costs of
community-acquired colonization with multidrug-resistant organisms at a
German teaching hospital. BMC Health Serv Res. 2018;18:737.",Enterococcus,efa,vancomycin,COL,Engler-Huesch,2018,01/2011-12/2014,Matched case-cohort design,Germany,1004,7917,1,DRI,,,mean,sd,10.56,,,9.85,8.93,,,9.21,,,,,,,,1,79,FALSE,FALSE,FALSE
cassini_52,"Epstein L, Hunter JC, Arwady MA, et al. New Delhi metallo-beta-lactamase-producing carbapenem-resistant escherichia coli associated with exposure to duodenoscopes. JAMA - Journal of the American Medical Association. 2014;312(14):1447-1455.",Escherichia coli,eco,carbapenems,COL,Epstein,2014,01/13-12/13,Case-control study,USA,8,27,1,DRI,,,mean,sd,13.3,,,12,30.2,,,13.2,,1,37,14,65,,,0,0,FALSE,FALSE,TRUE
cassini_236,"Ericson JE, Popoola VO, Smith PB, et al. Burden of Invasive Staphylococcus aureus Infections in Hospitalized Infants. JAMA pediatrics. Dec 2015;169(12):1105-1111.",Staphylococcus aureus,sau,methicillin,INF,Ericson,2015,1997-2012,Multicentre retrospective study,USA,1063,2825,1,AMR,,,mean,pvalue,64,,,,64,,,,0.8,,,,,,"NICU patients, matched on NICU",0,0,FALSE,FALSE,FALSE
cassini_4,"Esterly JS, Griffith M, Qi C, Malczynski M, Postelnick MJ, Scheetz MH. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrobial agents and chemotherapy. Oct 2011;55(10):4844-4849.",Acinetobacter baumannii,aba,carbapenems,BSI,Esterly,2011,01/05- 12/08,Retrospective cohort study,USA,37,42,1,AMR,,,median,IQR,16,1,0,,0,0,9,,,,,,,,Prior isolation,0,0,FALSE,FALSE,FALSE
cassini_89,"Esteve-Palau E, Solande G, Sanchez F, et al. Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: A matched cohort study. The Journal of infection. Dec 2015;71(6):667-674.",Escherichia coli,eco,3g cephalosporins,UTI,Esteve-Palau,2015,08/10-07/13,Matched cohort study,Spain,60,60,1,AMR,,,mean,sd,11.6,,,1.5,7.5,,,0.8,0.02,,,,,,"matched on sex, age, date of admission",1,3,FALSE,FALSE,FALSE
naylor_57,"Esteve-Palau E, Solande G, Sanchez F, Sorli L, Montero M, Guerri R, et al. Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: A matched cohort study. Journal of Infection. 2015;71:667–74. ",Escherichia coli,eco,3g cephalosporins,UTI,Esteve-Palau,2015,08/10-07/13,Matched cohort study,Spain,60,60,0,AMR,2013,EUR,mean,95ci,3611,2619,7141,,2502,1716,4318,,0.007,,,,,,"matched on sex, age, date of admission (p<0.001)",1,3,FALSE,FALSE,FALSE
cassini_126,"Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. The Journal of antimicrobial chemotherapy. Nov 2007;60(5):1124-1130.",Klebsiella pneumoniae,kpn,carbapenems,INF,Falagas,2007,10/00-04/06 & 10/03-04/06,Matched case-control,Greece,53,53,1,AMR,,,mean,sd,21.4,,,23.9,15.3,,,19.9,,,,,,,,0,0,FALSE,FALSE,FALSE
zhen_46,"Filice GA, Nyman JA, Lexau C, Lees CH, Bockstedt LA, Como-Sabetti K, et al.
Excess costs and utilization associated with methicillin resistance for
patients with Staphylococcus aureus infection. Infect Control Hosp
Epidemiol. 2010;31:365–73",Staphylococcus aureus,sau,methicillin,INF,Filice,2015,01/2004-06/2006.,Cohort,USA,335,390,0,AMR,2015,USD,median,range,30027,5178,99399,,7712,0,40102,,,,,,,,,0,0,FALSE,FALSE,FALSE
zhen_59,"Ford CD, Lopansri BK, Haydoura S, Snow G, Dascomb KK, Asch J, et al.
Frequency, risk factors, and outcomes of vancomycin-resistant Enterococcus
colonization and infection in patients with newly diagnosed acute leukemia:
 different patterns in patients with acute myelogenous and acute lymphoblastic leukemia. Infect Control Hosp Epidemiol. 2015;36:47–53.",Enterococcus,efa,vancomycin,BSI,Ford,2015,10/2006-12/2012,Retrospective clinical stud,USA,15,199,0,DRI,2014,USD,median,pvalue,172000,,,,86000,,,,0.0003,,,,,,newly diagnosed acute leukemia patients,1,80,FALSE,FALSE,FALSE
zhen_59,"Ford CD, Lopansri BK, Haydoura S, Snow G, Dascomb KK, Asch J, et al.
Frequency, risk factors, and outcomes of vancomycin-resistant Enterococcus
colonization and infection in patients with newly diagnosed acute leukemia:
 different patterns in patients with acute myelogenous and acute lymphoblastic leukemia. Infect Control Hosp Epidemiol. 2015;36:47–53.",Enterococcus,efa,vancomycin,BSI,Ford,2015,10/2006-12/2012,Retrospective clinical stud,USA,15,199,1,DRI,,,median,pvalue,42,,,,29,,,,0.0005,,,,,,newly diagnosed acute leukemia patients,1,80,FALSE,FALSE,FALSE
cassini_215,"Fortuin-de Smidt MC, Singh-Moodley A, Badat R, et al. Staphylococcus aureus bacteraemia in Gauteng academic hospitals, South Africa. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Jan 2015;30:41-48.",Staphylococcus aureus,sau,methicillin,BSI,Fortuin-de Smidt,2012,09/12-09/13,cross sectional study,South Africa,86,154,1,AMR,,,median,IQR,38,14,64,,19,7,33,,,,,,,,,0,0,FALSE,FALSE,FALSE
naylor_63,"Francis JR, Blyth CC, Colby S, Fagan JM, Waring J. Multidrug-resistant tuberculosis in Western Australia, 1998–2012. The Medical Journal of Australia. 2014;200:328–32. ",Tuberculosis,tb,MDR,RTI,Francis,2014,01/1998-12/2012,Restropsective case-control,Australia,16,48,1,AMR,,,mean,range,26,1,99,,13,2,41,,,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_319,"Garbutt JM, Ventrapragada M, Littenberg B, Mundy LM. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Mar 2000;30(3):466-472.",Enterococcus faecium,efa,vancomycin,BSI,Garbutt,2000,"1995-1997","Retrospective cohort",USA,46,23,1,AMR,,,mean,sd,39.7,,,25.5,21,,,16.3,0.0019,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_74,"Garcia Hernandez A, Garcia-Vazquez E, Gomez Gomez J, Canteras M, Hernandez-Torres A, Ruiz Gomez J. [Predictive factors of ESBL versus non-ESBL Escherichia coli bacteraemia and influence of resistance on the mortality of the patients. Medicina clinica. Jan 29 2011;136(2):56-60.",Escherichia coli,eco,3g cephalosporins,BSI,Garcia-Hernandez,2011,01/06-07/07,Prospective cohort,Spain,34,119,1,AMR,,,mean,sd,24.3,,,22,20.9,,,26.7,,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_13,"Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. May 1 2003;36(9):1111-1118.",Acinetobacter baumannii,aba,carbapenems,RTI,Garnacho-Montero,2003,01/97-06/01,Prospective cohort,Spain,21,14,1,AMR,,,mean,sd,45.2,,,30.7,53.9,,,50,,,,,,,"underlying conditions, cases treated with colistin, controls with imipenem-cilastatin *occurring during treatment, when signs of pneumonia remained and due to septic shock",0,0,FALSE,FALSE,TRUE
zhen_64,"Gearhart M, Martin J, Rudich S, Thomas M, Wetzel D, Solomkin J, et al.
Consequences of vancomycin-resistant Enterococcus in liver transplant
recipients: a matched control study. Clin Transpl. 2005;19:711–6.",Enterococcus,efa,vancomycin,INF,Gearhart,2005,1995-2002,Retrospective ,USA,19,38,0,DRI,2002,USD,mean,pvalue,78592,,,,35567,,,,0.07,,,,,,"Liver transplant recipients, cost year taken as final study year, reports p<0.07, but seems very specific so assumed = (<typo)",1,83,FALSE,FALSE,FALSE
zhen_64,"Gearhart M, Martin J, Rudich S, Thomas M, Wetzel D, Solomkin J, et al.
Consequences of vancomycin-resistant Enterococcus in liver transplant
recipients: a matched control study. Clin Transpl. 2005;19:711–6.",Enterococcus,efa,vancomycin,INF,Gearhart,2005,1995-2002,Retrospective ,USA,19,38,1,DRI,,,mean,pvalue,42.5,,,,21.7,,,,0.006,,,,,,"Liver transplant recipients, cost year taken as final study year, reports p<0.006, but seems very specific so assumed = (<typo)",1,83,FALSE,FALSE,FALSE
cassini_111,"Giannella M, Morelli MC, Cristini F, et al. Carbapenem-resistant Klebsiella pneumoniae colonization at liver transplantation: a management challenge. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. May 2014;20(5):631-633.",Klebsiella pneumoniae,kpn,carbapenems,COL/INF,Giannella,2014,06/11- 06/13,Matched case-control study,Italy,10,20,1,DRI,,,median,range,16,14,27,,20,15,62,,0.37,,,,,,"liver transplant patients, 4 patients developed a CR-KP infectionwithin a median of 33 days (interquartile range511-56 days)",0,0,FALSE,FALSE,TRUE
cassini_207,"Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Nov 1999;29(5):1171-1177.",Staphylococcus aureus,sau,methicillin,RTI,Gonzalez,1999,01/90-12/95,Retrospective cohort study,Spain,32,54,1,AMR,,,mean,sd,44.4,,,27.7,30.3,,,21.7,,,,,,,,0,0,FALSE,FALSE,FALSE
naylor_68,"Gürntke S, Kohler C, Steinmetz I, Pfeifer Y, Eller C, Gastmeier P, et al. Molecular epidemiology of extended-spectrum beta-lactamase (ESBL)-positive Klebsiella pneumoniae from bloodstream infections and risk factors for mortality. Journal of Infection and Chemotherapy. Elsevier Ltd; 2014;20:817–9. ",Klebsiella pneumoniae,kpn,ESBL,BSI,Gurntke,2014,01/08-12/13,Cohort,Germany,66,286,1,AMR,,,median,IQR,18,9,42,,12,7,25,,0.027,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_182,"Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med. Jan 26 1998;158(2):182-189.",Staphylococcus aureus,sau,methicillin,BSI,Harbarth,1998,01/89-12/95,Case-control study,Switzerland,38,38,1,AMR,,,median,range,30,1,141,,23,1,178,,,,,,,,"note from cassini - age, LOS, nr.comorbidities, McCabe score, Jackson score",0,0,FALSE,FALSE,FALSE
cassini_93,"Hayakawa K, Gattu S, Marchaim D, et al. Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum beta-lactamase in a large U.S. Medical Center. Antimicrobial agents and chemotherapy. Aug 2013;57(8):4010-4018.",Klebsiella pnuemoniae,kpn,carbapenems,INF,Hayakawa,2013,02/10-07/11,Retrospective case-case-control study,USA,319,58,1,AMR,,,median,IQR,7,4,12,,7,3,20,,0.579,,,,,,Excluding the patients who died during the hospitalization,0,0,FALSE,FALSE,FALSE
cassini_93,"Hayakawa K, Gattu S, Marchaim D, et al. Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum beta-lactamase in a large U.S. Medical Center. Antimicrobial agents and chemotherapy. Aug 2013;57(8):4010-4018.",Klebsiella pnuemoniae,kpn,carbapenems,INF,Hayakawa,2013,02/10-07/11,Retrospective case-case-control study,USA,319,319,1,DRI,,,median,IQR,7,4,12,,4,2,6,,,,,,,,"Excluding the patients who died during the hospitalization, p< 0.001",0,0,FALSE,FALSE,FALSE
cassini_15,"Henig O, Weber G, Hoshen MB, et al. Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and infection: matched case-control study. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. Oct 2015;34(10):2063-2068.",Acinetobacter baumannii,aba,carbapenems,COL/INF,Henig,2015,01/07-12/12,Matched case-control study,Israel,1190,1190,1,DRI,,,median,range,18,0,97,,17,0,96,,,,,,,,"P<0.0001, ""Most of the CRAB isolates were from the respiratory tract (42.6 %), followed by blood (20 %), non-sterile sources, and urine.""",0,0,FALSE,FALSE,FALSE
cassini_15,"Henig O, Weber G, Hoshen MB, et al. Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and infection: matched case-control study. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. Oct 2015;34(10):2063-2068.",Acinetobacter baumannii,aba,carbapenems,BSI,Henig,2015,01/07-12/12,Matched case-control study,Israel,241,241,1,DRI,,,median,range,16,1,85,,15,1,91,,,,,,,,non-significant,0,0,FALSE,FALSE,FALSE
cassini_201,"Hershow RC, Khayr WF, Smith NL. A comparison of clinical virulence of nosocomially acquired methicillin-resistant and methicillin-sensitive Staphylococcus aureus infections in a university hospital. Infection control and hospital epidemiology. Oct 1992;13(10):587-593.",Staphylococcus aureus,sau,methicillin,INF,Hershow,1992,01/89-12/89,Retrospective cohort study,USA,22,22,1,AMR,,,median,range,14,5,28,,10,5,21,,0.41,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_244,"Hill DM, Schroeppel TJ, Magnotti LJ, et al. Methicillin-resistant Staphylococcus aureus in early ventilator-associated pneumonia: cause for concern? Surgical infections. Dec 2013;14(6):520-524.",Staphylococcus aureus,sau,methicillin,RTI,Hill,2013,01/04-12/09,Retrospective study,USA,80,60,1,AMR,,,mean,pvalue,34,,,,35,,,,0.756,,,,,,all patients had VAP,0,0,FALSE,FALSE,TRUE
cassini_68,"Hsieh CJ, Shen YH, Hwang KP. Clinical implications, risk factors and mortality following community-onset bacteremia caused by extended-spectrum beta-lactamase (ESBL) and non-ESBL producing Escherichia coli. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. Jun 2010;43(3):240-248.",Escherichia coli,eco,3g cephalosporins,BSI,Hsieh,2010,01/05-12/06,Retrospective cohort study,China,19,385,1,AMR,,,mean,sd,15.5,,,8.5,6.1,,,6.9,,,,,,,"patients with community onset infection, emergency visits",0,0,FALSE,FALSE,FALSE
cassini_5,"Huang ST, Chiang MC, Kuo SC, et al. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. Oct 2012;45(5):356-362.",Acinetobacter baumannii,aba,carbapenems,BSI,Huang,2012,06/02-12/07,Retrospective cohort study,Taiwan,62,164,1,AMR,,,mean,sd,35.9,,,33.6,28.2,,,44,,,,,,,Prior isolation,0,0,FALSE,FALSE,FALSE
zhen_90,"Huang W, Qiao F, Zhang Y, Huang J, Deng Y, Li J, et al. In-hospital medical
costs of infections caused by carbapenem-resistant Klebsiella pneumoniae.
Clin Infect Dis. 2018;672:S225–30",Klebsiella pneumoniae,kpn,carbapenems,INF,Huang,2017,01/17-12/17,Retrospective cohort study,China,267,1328,1,AMR,,,median,range,21,10,44,,18,9,46,,,,,,,,Post infection,1,39,FALSE,FALSE,FALSE
zhen_90,"Huang W, Qiao F, Zhang Y, Huang J, Deng Y, Li J, et al. In-hospital medical
costs of infections caused by carbapenem-resistant Klebsiella pneumoniae.
Clin Infect Dis. 2018;672:S225–30",Klebsiella pneumoniae,kpn,carbapenems,INF,Huang,2017,01/17-12/17,Retrospective cohort study,China,237,237,0,AMR,2017,USD,median,range,9215,3358,20859,,6904,2641,15336,,,,,,,0.003,Post infection,1,39,FALSE,FALSE,FALSE
cassini_202,"Hulten KG, Kaplan SL, Lamberth LB, et al. Hospital-acquired Staphylococcus aureus infections at Texas Children's Hospital, 2001-2007. Infection control and hospital epidemiology. Feb 2010;31(2):183-190.",Staphylococcus aureus,sau,methicillin,INF,Hulten,2010,08/01-07/07,Retrospective cohort study,USA,69,14,1,AMR,,,median,range,29,3,339,,29,9,405,,,,,,,,"USA300 strain, Extracted different results to those in Cassini – think they extracted one strain of MRSA vs other strains of MRSA (but then discrepancies in sample sizes, have used figures from paper)",0,0,FALSE,FALSE,FALSE
cassini_202,"Hulten KG, Kaplan SL, Lamberth LB, et al. Hospital-acquired Staphylococcus aureus infections at Texas Children's Hospital, 2001-2007. Infection control and hospital epidemiology. Feb 2010;31(2):183-190.",Staphylococcus aureus,sau,methicillin,INF,Hulten,2010,08/01-07/07,Retrospective cohort study,USA,26,133,1,AMR,,,median,range,56,0,158,,49,0,418,,,,,,,,"non-USA300 strain, Extracted different results to those in Cassini – think they extracted one strain of MRSA vs other strains of MRSA (but then discrepancies in sample sizes, have used figures from paper)",0,0,FALSE,FALSE,FALSE
cassini_105,"Hussein K, Raz-Pasteur A, Finkelstein R, et al. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae. Journal of Hospital Infection. 2013;83(4):307-313.",Klebsiella pneumoniae,kpn,carbapenems,BSI,Hussein,2013,01/06-12/08,Retrospective case-control study,Israel,103,214,1,AMR,,,median,range,17,1,125,,12,1,202,,,,,,,,,0,0,FALSE,FALSE,FALSE
naylor_88,"Issler-Fisher AC, McKew G, Fisher OM, Harish V, Gottlieb T, Maitz PKM. Risk factors for, and the effect of MRSA colonization on the clinical outcomes of severely burnt patients. Burns. Elsevier Ltd and International Society of Burns Injuries; 2015;41:1212–20. ",Staphylococcus,sau,methicillin,COL/INF,Issler-Fisher,2015,01/2012-10/2013,Retrospective case-control,Australia,57,300,1,DRI,,,median,IQR,25.5,17.8,35.8,,8,4,14.2,,,,,,,,"p<0.001, in burn patients",0,0,FALSE,FALSE,FALSE
zhen_70,"Jiang HL, Zhou Z, Wang LS, Fang Y, Li YH, Chu CI. The risk factors, costs, and
survival analysis of invasive VRE infections at a medical center in eastern
Taiwan. Int J Infect Dis. 2017;54:18–24.",Enterococcus,efa,vancomycin,INF,Jiang,2017,2007 - 2012,Cohort,Taiwan,48,142,1,AMR,,,mean,sd,32.5,,,34.3,24.2,,,25.9,0.082,,,,,,after infection,0,0,FALSE,FALSE,FALSE
cassini_122,"Jiao Y, Qin Y, Liu J, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization and predictors of mortality: a retrospective study. Pathogens and global health. Mar 2015;109(2):68-74.",Klebsiella pneumoniae,kpn,carbapenems,COL/INF,Jiao,2015,01/10-1/11,Retrospective case-control study,China,30,30,1,AMR,,,mean,sd,33.8,,,30.8,18,,,23.4,,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_203,"Joo EJ, Chung DR, Ha YE, et al. Clinical predictors of community-genotype ST72-methicillin-resistant Staphylococcus aureus-SCCmec type IV in patients with community-onset S. aureus infection. The Journal of antimicrobial chemotherapy. Jul 2012;67(7):1755-1759.",Staphylococcus aureus,sau,methicillin,INF,Joo,2012,2007-2009,Matched case-control study,South Korea,84,84,1,AMR,,,median,range,20,2,202,,22,2,158,,0.085,,,,,,"admission date, gives breakdown of types of infections",0,0,FALSE,FALSE,TRUE
cassini_255,"Joo EJ, Kang CI, Ha YE, et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microbial drug resistance (Larchmont, N.Y.). Jun 2011;17(2):305-312.",Pseudomonas aeruginosa,pae,carbapenems,BSI,Joo,2011,10/07-03/09,Retrospective cohort study,South Korea,46,156,1,AMR,,,median,IQR,16,14,42,,16,9,29,,,,,,,,"adjusted for corticosteroid use, nosocomial acquisition, polymicrobial infection, Charlson’s weighted index of co-morbidity, and admission to ICUs",0,0,FALSE,FALSE,FALSE
cassini_263,"Judd WR, Ratliff PD, Hickson RP, Stephens DM, Kennedy CA. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients. American journal of infection control. 2016;44(11):1275-1279.",Pseudomonas aeruginosa,pae,carbapenems,INF,Judd,2016,01/11-12/13,Retrospective observational,USA,32,350,1,AMR,,,median,IQR,14,8,29,,9,5,15,,,,,,,,0.004,1,102,FALSE,FALSE,FALSE
cassini_263,"Judd WR, Ratliff PD, Hickson RP, Stephens DM, Kennedy CA. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients. American journal of infection control. 2016;44(11):1275-1279.",Pseudomonas aeruginosa,pae,carbapenems,INF,Judd,2016,01/11-12/13,Retrospective observational,USA,32,350,0,AMR,2013,USD,median,IQR,37331,17141,77333,,15995,8542,31811,,,,,,,,,1,102,FALSE,FALSE,FALSE
zhen_68,"Jung E, Byun S, Lee H, Moon SY, Lee H. Vancomycin-resistant Enterococcus
colonization in the intensive care unit: clinical outcomes and attributable
costs of hospitalization. Am J Infect Control. 2014;42:1062–6.",Enterococcus,efa,vancomycin,COL,Jung ,2014,01/2008-12/2010,Retrospective matched cohort,South Korea,199,199,0,DRI,2014,KRW,excess,pvalue,627632,,,,,,,,0.268,,,,,,,1,89,FALSE,FALSE,FALSE
zhen_68,"Jung E, Byun S, Lee H, Moon SY, Lee H. Vancomycin-resistant Enterococcus
colonization in the intensive care unit: clinical outcomes and attributable
costs of hospitalization. Am J Infect Control. 2014;42:1062–6.",Enterococcus,efa,vancomycin,COL,Jung ,2014,01/2008-12/2010,Retrospective matched cohort,South Korea,199,199,1,DRI,,,excess,pvalue,5.35,,,,,,,,0.004,,,,,,,1,89,FALSE,FALSE,FALSE
cassini_339,"Khair HN, VanTassell P, Henderson JP, Warren DK, Marschall J, Program CDCPE. Vancomycin resistance has no influence on outcomes of enterococcal bacteriuria. The Journal of hospital infection. Nov 2013;85(3):183-188.",Enterococcus faecium,efa,vancomycin,UTI,Khair,2013,2011,Prospective cohort study,USA,74,180,1,AMR,,,mean,range,6.8,0.1,150.8,,5,0.2,78.2,,0.08,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_146,"Kim BN, Woo JH, Kim MN, Ryu J, Kim YS. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. The Journal of hospital infection. Oct 2002;52(2):99-106.",Klebsiella pneumoniae,kpn,3g cephalosporins,BSI,Kim,2002,07/96-06/00,Retrospective cohort study,South Korea,44,118,1,AMR,,,mean,pvalue,39.6,,,,23.9,,,,0.008,,,,,,,0,0,FALSE,FALSE,FALSE
naylor_95,"Kim C-J, Kim H-B, Oh M, Kim YYK, Kim A, Oh S-H, et al. The burden of nosocomial staphylococcus aureus bloodstream infection in South Korea: a prospective hospital-based nationwide study. BMC infectious diseases. 2014;14:590. ",Staphylococcus aureus,sau,methicillin,BSI,Kim,2014,07/11-09/11,Cohort,South Korea,133,57,0,AMR,2011,USD,median,IQR,19318,9852,29438,,8030,4998,17733,,,,,,,,"adults, both resistant and susceptible compared to non-infected (matched, same numbers respectively)",1,4,FALSE,FALSE,FALSE
naylor_95,"Kim C-J, Kim H-B, Oh M, Kim YYK, Kim A, Oh S-H, et al. The burden of nosocomial staphylococcus aureus bloodstream infection in South Korea: a prospective hospital-based nationwide study. BMC infectious diseases. 2014;14:590. ",Staphylococcus aureus,sau,methicillin,BSI,Kim,2014,07/11-09/11,Cohort,South Korea,133,57,1,AMR,,,mean,sd,38.5,,,26.8,29.4,,,20.7,,,,,,,"adults, both resistant and susceptible compared to non-infected (matched, same numbers respectively)",1,4,FALSE,FALSE,FALSE
naylor_95,"Kim C-J, Kim H-B, Oh M, Kim YYK, Kim A, Oh S-H, et al. The burden of nosocomial staphylococcus aureus bloodstream infection in South Korea: a prospective hospital-based nationwide study. BMC infectious diseases. 2014;14:590. ",Staphylococcus aureus,sau,methicillin,BSI,Kim,2014,07/11-09/11,Cohort,South Korea,133,133,1,DRI,,,mean,sd,38.5,,,26.8,25.8,,,28,,,,,,,,0,0,FALSE,FALSE,FALSE
naylor_95,"Kim C-J, Kim H-B, Oh M, Kim YYK, Kim A, Oh S-H, et al. The burden of nosocomial staphylococcus aureus bloodstream infection in South Korea: a prospective hospital-based nationwide study. BMC infectious diseases. 2014;14:590. ",Staphylococcus aureus,sau,methicillin,BSI,Kim,2014,07/11-09/11,Cohort,South Korea,133,133,0,DRI,2011,USD,median,IQR,19318,9852,29438,,7092,2864,,14609,,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_1,"Kim SB, Min YH, Cheong JW, et al. Incidence and risk factors for carbapenem- and multidrug-resistant Acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients. Scandinavian journal of infectious diseases. Feb 2014;46(2):81-88.",Acinetobacter baumannii,aba,carbapenems,BSI,Kim,2014,01/05-12/11,Restropsective case-control study,South Korea,19,38,1,DRI,,,median,range,35,30,47,,29,26.75,34,,,,,,,,hematopoietic stem cell transplantation patients,0,0,FALSE,FALSE,FALSE
naylor_99,"Kini AR, Shetty V, Kumar AM, Shetty SM, Shetty A. Community-associated, methicillin-susceptible, and methicillin-resistant Staphylococcus aureus bone and joint infections in children. Journal of Pediatric Orthopaedics B. 2013;22:158–66. ",Staphylococcus aureus,sau,methicillin,B-J,Kini,2013,01/04-12/08,Retrospective cohort study,India,41,33,1,AMR,,,mean,range,16.6,7,34,,10.5,4,23,,,,,,,,"<18 years old, bone and joint",0,0,FALSE,FALSE,FALSE
zhen_26,"Klein EY, Jiang W, Mojica N, Tseng KK, McNeill R, Cosgrove SE, et al. National
costs associated with methicillin-susceptible and methicillin-resistant
Staphylococcus aureus hospitalizations in the United States, 2010-2014. Clin
Infect Dis. 2019;68:22–8.",Staphylococcus aureus,sau,methicillin,BSI,Klein,2019,2010-2014,Cohort,USA,54255,57065,0,AMR,2014,USD,mean,95ci,34526,32918,36134,,34175,32347,36002,,0.69,,,,,,Septicemia,1,11,FALSE,FALSE,FALSE
zhen_26,"Klein EY, Jiang W, Mojica N, Tseng KK, McNeill R, Cosgrove SE, et al. National
costs associated with methicillin-susceptible and methicillin-resistant
Staphylococcus aureus hospitalizations in the United States, 2010-2014. Clin
Infect Dis. 2019;68:22–8.",Staphylococcus aureus,sau,methicillin,BSI,Klein,2019,2010-2014,Cohort,USA,54255,57065,1,AMR,,,median,IQR,10,6,17,,9,6,15,,,,,,,,Septicemia,1,11,FALSE,FALSE,FALSE
zhen_26,"Klein EY, Jiang W, Mojica N, Tseng KK, McNeill R, Cosgrove SE, et al. National
costs associated with methicillin-susceptible and methicillin-resistant
Staphylococcus aureus hospitalizations in the United States, 2010-2014. Clin
Infect Dis. 2019;68:22–8.",Staphylococcus aureus,sau,methicillin,INF,Klein,2019,2010-2014,Cohort,USA,358140,257930,1,AMR,,,median,IQR,6,4,11,,7,4,12,,,,,,,,All,0,0,FALSE,FALSE,TRUE
zhen_26,"Klein EY, Jiang W, Mojica N, Tseng KK, McNeill R, Cosgrove SE, et al. National
costs associated with methicillin-susceptible and methicillin-resistant
Staphylococcus aureus hospitalizations in the United States, 2010-2014. Clin
Infect Dis. 2019;68:22–8.",Staphylococcus aureus,sau,methicillin,RTI,Klein,2019,2010-2014,Cohort,USA,48780,25020,1,AMR,,,median,IQR,10,6,18,,12,7,20,,,,,,,,Pneumonia,1,54,FALSE,FALSE,TRUE
zhen_26,"Klein EY, Jiang W, Mojica N, Tseng KK, McNeill R, Cosgrove SE, et al. National
costs associated with methicillin-susceptible and methicillin-resistant
Staphylococcus aureus hospitalizations in the United States, 2010-2014. Clin
Infect Dis. 2019;68:22–8.",Staphylococcus aureus,sau,methicillin,RTI,Klein,2019,2010-2014,Cohort,USA,48780,25020,0,AMR,2014,USD,mean,95ci,38561,36811,40725,,40725,38717,42733,,0.045,,,,,,Pneumonia,1,54,FALSE,FALSE,TRUE
zhen_26,"Klein EY, Jiang W, Mojica N, Tseng KK, McNeill R, Cosgrove SE, et al. National
costs associated with methicillin-susceptible and methicillin-resistant
Staphylococcus aureus hospitalizations in the United States, 2010-2014. Clin
Infect Dis. 2019;68:22–8.",Staphylococcus aureus,sau,methicillin,INF,Klein,2019,2010-2014,Cohort,USA,255105,175845,1,AMR,,,median,IQR,5,3,9,,6,3,9,,,,,,,,Other,1,55,FALSE,FALSE,TRUE
zhen_26,"Klein EY, Jiang W, Mojica N, Tseng KK, McNeill R, Cosgrove SE, et al. National
costs associated with methicillin-susceptible and methicillin-resistant
Staphylococcus aureus hospitalizations in the United States, 2010-2014. Clin
Infect Dis. 2019;68:22–8.",Staphylococcus aureus,sau,methicillin,INF,Klein,2019,2010-2014,Cohort,USA,255105,175845,0,AMR,2014,USD,mean,95ci,14792,14383,15201,,15578,15079,16077,,,,,,,,"Other, p<0.001",1,55,FALSE,FALSE,TRUE
zhen_35,"Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of
methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann
Pharmacother. 2004;38:1377–82.",Staphylococcus aureus,sau,methicillin,INF,Kopp,2004,01/1999-12/2000,Cohort,USA,34,34,0,AMR,2000,USD,median,IQR,16575,7275,89157,,12862,5292,36471,,0.11,,,,,,,1,12,FALSE,FALSE,FALSE
zhen_35,"Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of
methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann
Pharmacother. 2004;38:1377–82.",Staphylococcus aureus,sau,methicillin,INF,Kopp,2004,01/1999-12/2000,Cohort,USA,34,34,1,AMR,,,median,IQR,15.5,7.5,35.5,,11,2,18.5,,0.054,,,,,,,1,12,FALSE,FALSE,FALSE
zhen_60,"Kramer TS, Remschmidt C, Werner S, Behnke M, Schwab F, Werner G, et al.
The importance of adjusting for enterococcus species when assessing the
burden of vancomycin resistance: a cohort study including over 1000 cases
of enterococcal bloodstream infections. Antimicrob Resist Infect Control.
2018;7:133.",Enterococcus,efa,vancomycin,BSI,Kramer,2018,01/2008-12/2015,Retrospective cohort study,Germany,103,493,1,AMR,,,median,IQR,54,36,85,,42,23,75,,0.01,,,,,,total hospital stay,1,31,FALSE,FALSE,FALSE
zhen_60,"Kramer TS, Remschmidt C, Werner S, Behnke M, Schwab F, Werner G, et al.
The importance of adjusting for enterococcus species when assessing the
burden of vancomycin resistance: a cohort study including over 1000 cases
of enterococcal bloodstream infections. Antimicrob Resist Infect Control.
2018;7:133.",Enterococcus,efa,vancomycin,BSI,Kramer,2018,01/2008-12/2015,Retrospective cohort study,Germany,103,493,0,AMR,2015,USD,excess_median,IQR,32274,28117,41765,,,,,,,,,,,,total hospital stay,1,31,FALSE,FALSE,FALSE
cassini_158,"Kuo KC, Shen YH, Hwang KP. Clinical implications and risk factors of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection in children: a case-control retrospective study in a medical center in southern Taiwan. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. Jun 2007;40(3):248-254.",Klebsiella pneumoniae,kpn,ESBL,INF,Kuo,2007,"01/00-10/05",Case-control study,Taiwan,54,54,1,AMR,,,mean,sd,34.4,,,5.2,14.3,,,2.3,,,,,,,"matching on type of speciment, date of isolation, P<0.001, "". Of these 54 K. pneumoniae isolates, seventeen
isolates were from blood, six from central venous
catheter tip, 22 from urine, eight from pus, and one from
bronchioalveolar lavage""",0,0,FALSE,FALSE,FALSE
cassini_50,"Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38.",Escherichia coli,eco,3g cephalosporins,BSI,Lambert,2011,01/05-12/08,Retrospective cohort study,Europe,21,131,1,AMR,,,median,IQR,16,4,24,,9,5,20,,,,,,,,"post infection, ICU patients, discharged alive",0,0,FALSE,FALSE,FALSE
cassini_50,"Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38.",Escherichia coli,eco,3g cephalosporins,BSI,Lambert,2011,01/05-12/08,Retrospective cohort study,Europe,21,86,1,AMR,,,median,IQR,14,2,37,,7,3,17,,,,,,,,"post infection, ICU patients, discharged dead",0,0,FALSE,FALSE,FALSE
cassini_50,"Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38.",Escherichia coli,eco,3g cephalosporins,RTI,Lambert,2011,01/05-12/08,Retrospective cohort study,Europe,31,327,1,AMR,,,median,IQR,18,11,29,,17,9,29,,,,,,,,"post infection, ICU patients, discharged alive",0,0,FALSE,FALSE,FALSE
cassini_50,"Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38.",Escherichia coli,eco,3g cephalosporins,RTI,Lambert,2011,01/05-12/08,Retrospective cohort study,Europe,27,134,1,AMR,,,median,IQR,11,3,25,,11,5,24,,,,,,,,"post infection, ICU patients, discharged dead",0,0,FALSE,FALSE,FALSE
cassini_50,"Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38.",Staphylococcus aureus,sau,methicillin,BSI,Lambert,2011,01/05-12/08,Prospective cohort study,Europe,106,210,1,AMR,,,median,IQR,14,6,24,,11,5,24,,,,,,,,"post infection, ICU patients, discharged alive",0,0,FALSE,FALSE,FALSE
cassini_50,"Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38.",Staphylococcus aureus,sau,methicillin,BSI,Lambert,2011,01/05-12/08,Prospective cohort study,Europe,65,74,1,AMR,,,median,IQR,11,4,21,,7,2,19,,,,,,,,"post infection, ICU patients, discharged dead",0,0,FALSE,FALSE,FALSE
cassini_50,"Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38.",Staphylococcus aureus,sau,methicillin,RTI,Lambert,2011,01/05-12/08,Prospective cohort study,Europe,348,774,1,AMR,,,median,IQR,15,8,27,,14,8,25,,,,,,,,"post infection, ICU patients, discharged alive",0,0,FALSE,FALSE,FALSE
cassini_50,"Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38.",Staphylococcus aureus,sau,methicillin,RTI,Lambert,2011,01/05-12/08,Prospective cohort study,Europe,172,236,1,AMR,,,median,IQR,10,5,22,,8,4,18,,,,,,,,"post infection, ICU patients, discharged dead",0,0,FALSE,FALSE,FALSE
cassini_50,"Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38.",Pseudomonas aeruginosa,pae,ceftazidime,BSI,Lambert,2011,01/05-12/08,Cohort study,Europe,48,171,1,AMR,,,median,IQR,16,7,33,,14,6,26,,,,,,,,"post infection, ICU patients, discharged alive",0,0,FALSE,FALSE,FALSE
cassini_50,"Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38.",Pseudomonas aeruginosa,pae,ceftazidime,BSI,Lambert,2011,01/05-12/08,Cohort study,Europe,34,280,1,AMR,,,median,IQR,7,1,14,,7,2,18,,,,,,,,"post infection, ICU patients, discharged dead",0,0,FALSE,FALSE,FALSE
cassini_50,"Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38.",Pseudomonas aeruginosa,pae,ceftazidime,RTI,Lambert,2011,01/05-12/08,Cohort study,Europe,208,786,1,AMR,,,median,IQR,18,11,33,,16,9,29,,,,,,,,"post infection, ICU patients, discharged alive",0,0,FALSE,FALSE,FALSE
cassini_50,"Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38.",Pseudomonas aeruginosa,pae,ceftazidime,RTI,Lambert,2011,01/05-12/08,Cohort study,Europe,154,465,1,AMR,,,median,IQR,10,5,21,,13,5,24,,,,,,,,"post infection, ICU patients, discharged dead",0,0,FALSE,FALSE,TRUE
cassini_50,"Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38.",Acinetobacter baumannii,aba,ceftazidime,RTI,Lambert,2011,01/05-12/08,Cohort study,Europe,81,26,1,AMR,,,median,IQR,14,11,26,,25,14,40,,,,,,,,"post infection, ICU patients, discharged alive",0,0,FALSE,FALSE,TRUE
cassini_50,"Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38.",Acinetobacter baumannii,aba,ceftazidime,RTI,Lambert,2011,01/05-12/08,Cohort study,Europe,49,17,1,AMR,,,median,IQR,9,5,24,,15,10,25,,,,,,,,"post infection, ICU patients, discharged dead",0,0,FALSE,FALSE,TRUE
cassini_50,"Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38.",Acinetobacter baumannii,aba,ceftazidime,BSI,Lambert,2011,01/05-12/08,Cohort study,Europe,17,5,1,AMR,,,median,IQR,20,7,38,,9,2,13,,,,,,,,"post infection, ICU patients, discharged alive",0,0,FALSE,FALSE,FALSE
cassini_50,"Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: A cohort study. The Lancet Infectious Diseases. 2011;11(1):30-38.",Acinetobacter baumannii,aba,ceftazidime,BSI,Lambert,2011,01/05-12/08,Cohort study,Europe,13,6,1,AMR,,,median,IQR,5,1,16,,16,10,29,,,,,,,,"post infection, ICU patients, discharged dead",0,0,FALSE,FALSE,TRUE
cassini_333,"Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infection control and hospital epidemiology. May 1999;20(5):318-323.",Enterococcus faecium,efa,vancomycin,BSI,Lautenbach,1999,01/93-12/95,Historical cohort study,USA,72,188,1,AMR,,,median,95ci,23,19.18,27.83,,12,9,15,,,,,,,,"note p<0.001, matched on unit",0,0,FALSE,FALSE,FALSE
zhen_78,"Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extendedspectrum
beta-lactamase-producing Escherichia coli and Klebsiella
pneumoniae: risk factors for infection and impact of resistance on
outcomes. Clin Infect Dis. 2001;32:1162–71.",Enterobacteriaceae,ent,ESBL,INF,Lautenbach,2001,07/97-05/98,Restrospective cohort study,USA,33,66,1,AMR,,,median,range,11,0,167,,2,0,66,,0.003,,,,,,,0,0,FALSE,FALSE,FALSE
zhen_100,"Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, et al.
Epidemiology and impact of imipenem resistance in Acinetobacter
baumannii. Infect Control Hosp Epidemiol. 2009;30:1186–92.",Acinetobacter baumannii,aba,imipenem,COL/INF,Lautenbach,2009,01/89-12/04,Prospective cohort,USA,89,297,0,AMR,2015,USD,mean,95ci,393086,276636,509536,,276636,252785,396002,,0.03,,,,,,,1,41,FALSE,FALSE,FALSE
zhen_95,"Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, et al.
Imipenem resistance in Pseudomonas aeruginosa: emergence,
epidemiology, and impact on clinical and economic outcomes. Infect
Control Hosp Epidemiol. 2010;31:47–53. ",Pseudomonas aeruginosa,pae,imipenem,COL/INF,Lautenbach,2010,1980-2006,Case-control study,USA,253,2289,0,AMR,2015,USD,mean,95ci,295529,241780,349278,,241780,177913,212678,,,,,,,,p<0.001,0,0,FALSE,FALSE,FALSE
cassini_20,"Lautenbach E, Synnestvedt M, Weiner MG, et al. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infection control and hospital epidemiology. Dec 2009;30(12):1186-1192.",Acinetobacter baumannii,aba,imipenem,COL/INF,Lautenbach,2009,01/89-12/04,Prospective cohort,USA,89,297,1,AMR,,,median,range,21,14,29,,16,12,18,,0.07,,,,,,,1,41,FALSE,FALSE,FALSE
cassini_264,"Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infection control and hospital epidemiology. Sep 2006;27(9):893-900.",Pseudomonas aeruginosa,pae,imipenem,COL/INF,Lautenbach,2006,01/91-12/00,Case-control study,USA,142,737,1,AMR,,,median,IQR,15.5,5,31,,9,4,20,,,,,,,0.02,after culture,1,42,FALSE,FALSE,FALSE
zhen_92,"Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO.
Imipenem resistance among pseudomonas aeruginosa isolates: risk factors
for infection and impact of resistance on clinical and economic outcomes.
Infect Control Hosp Epidemiol. 2006;27:893–900.",Pseudomonas aeruginosa,pae,imipenem,COL/INF,Lautenbach,2006,01/91-12/00,Case-control study,USA,142,737,0,AMR,2015,USD,median,IQR,111871,39270,313857,,66549,26338,180391,,,,,,,,p<0.001,1,42,FALSE,FALSE,FALSE
cassini_153,"Lee JA, Kang CI, Joo EJ, et al. Epidemiology and clinical features of community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Microbial drug resistance (Larchmont, N.Y.). Jun 2011;17(2):267-273.",Klebsiella pneumoniae,kpn,3g cephalosporins,BSI,Lee,2011,01/02-09/09,Case-control study,South Korea,33,219,1,AMR,,,mean,sd,26.5,,,39,19.9,,,42.4,,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_218,"Lee JY, Chong YP, Kim T, et al. Bone and joint infection as a predictor of community-acquired methicillin-resistant Staphylococcus aureus bacteraemia: a comparative cohort study. The Journal of antimicrobial chemotherapy. Jul 2014;69(7):1966-1971.",Staphylococcus aureus,sau,methicillin,BSI,Lee,2014,01/04-12/12,Cohort,South Korea,31,138,1,AMR,,,median,IQR,47,19,87,,24,14,44.5,,,,,,,,,0,0,FALSE,FALSE,FALSE
zhen_79,"Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extendedspectrum
beta-lactamase-producing Escherichia coli and Klebsiella species
on clinical outcomes and hospital costs: a matched cohort study. Infect
Control Hosp Epidemiol. 2006;27:1226–32.",Enterobacteriaceae,ent,ESBL,INF,Lee,2006,no info,Cohort,USA,21,21,1,AMR,,,excess,95ci,9.7,3.2,14.6,,,,,,0.006,,,,,,"site other than UTI, taken from abstract  p <0.001",1,43,FALSE,FALSE,FALSE
zhen_79,"Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extendedspectrum
beta-lactamase-producing Escherichia coli and Klebsiella species
on clinical outcomes and hospital costs: a matched cohort study. Infect
Control Hosp Epidemiol. 2006;27:1226–32.",Enterobacteriaceae,ent,ESBL,INF,Lee,2006,no info,Cohort,USA,21,21,0,AMR,2015,USD,excess,sd,20641,,,28885,,,,,0.038,,,,,,"site other than UTI, taken from abstract  p <0.001",1,43,FALSE,FALSE,FALSE
naylor_114,"Leistner R, Bloch A, Sakellariou C, Gastmeier P, Schwab F. Costs and length of stay associated with extended-spectrum ?-lactamase production in cases of Escherichia coli bloodstream infection. Journal of Global Antimicrobial Resistance. Taibah University; 2014;2:107–9. ",Escherichia coli,eco,ESBL,BSI,Leistner,2014,01/2008-12/10,Cohort,Germany,92,92,1,AMR,,,median,pvalue,15,8,32,,17,8,38,,0.293,,,,,,"after infection, matched on age, sex; Charlson co-morbidity; and discharge year",1,103,FALSE,FALSE,TRUE
zhen_89,"Leistner R, Bloch A, Sakellariou C, Gastmeier P, Schwab F. Costs and length
of stay associated with extended-spectrum ?-lactamase production in cases
of Escherichia coli bloodstream infection. J Glob Antimicrob Resist. 2014;2:
107–9.",Escherichia coli,eco,ESBL,BSI,Leistner,2014,01/2008-12/10,Cohort,Germany,92,92,0,AMR,2010,EUR,median,IQR,15082,6263,41488,,16561,5599,47028,,0.359,,,,,,"total hospital cost, matched",1,103,FALSE,FALSE,TRUE
naylor_113,"Leistner R, Gürntke S, Sakellariou C, Denkel LA, Bloch A, Gastmeier P, et al. Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort. Infection. 2014;42:991–7. ",Enterobacteriaceae,ent,ESBL,BSI,Leistner,2014,01/2008-12/11,Cohort,Germany,244,1607,0,AMR,2011,EUR,median,IQR,22893,7024,62850,,9734,4003,27520,,,,,,,,p<0.001,1,13,FALSE,FALSE,FALSE
naylor_113,"Leistner R, Gürntke S, Sakellariou C, Denkel LA, Bloch A, Gastmeier P, et al. Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort. Infection. 2014;42:991–7. ",Enterobacteriaceae,ent,ESBL,BSI,Leistner,2014,01/2008-12/11,Cohort,Germany,244,1607,1,AMR,,,median,IQR,15,9,34,,12,7,23,,,,,,,,"p<0.001, total hospital cost,different from cassini et al extraction but in the actual referenced paper",1,13,FALSE,FALSE,FALSE
cassini_21,"Lemos EV, de la Hoz FP, Alvis N, et al. Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Feb 2014;20(2):174-180.",Acinetobacter baumannii,aba,carbapenems,INF,Lemos,2014,04/06-04/10,Prospective multicentre cohort,Colombia,104,61,1,AMR,,,mean,95ci,19.3,16,22.5,,16.2,11.5,19.9,,0.58,,,,,,"age, gender, APACHE II & infection site, adjusted model",1,14,FALSE,FALSE,FALSE
founou_51,"Lemos EV, Hoz FP, Alvis N, Einarson TR, Quevedo E, Castaneda C, et al. Impact of carbapenem resistance
on clinical and economic outcomes among patients with Acinetobacter baumannii infection in
Colombia. Clinical microbiology and infection: the official publication of the European Society of Clinical
Microbiology and Infectious Diseases. 2014; 20(2):174±80.",Acinetobacter baumannii,aba,carbapenems,INF,Lemos,2014,04/06-04/10,Prospective multicentre cohort,Colombia,104,61,0,AMR,2011,USD,excess,95ci,3057,1943,4134,,,,,,,,,,,,"p<0.001, adjusted model, hospital-costs",1,14,FALSE,FALSE,FALSE
zhen_32,"Li X, Chen Y, Gao W, Ouyang W, Wei J, Wen Z. Epidemiology and outcomes
of complicated skin and soft tissue infections among inpatients in southern
China from 2008 to 2013. PLoS One. 2016;11:e149960.",Staphylococcus aureus,sau,methicillin,SSTI,Li,2016,2008-2013,Cohort,China,61,14,0,AMR,2003,USD,mean,sd,37.93,,,47.2,18.89,,,13.57,0.12,,,,,,"""Complicated Skin and Soft Tissue Infections""",1,15,FALSE,FALSE,FALSE
zhen_32,"Li X, Chen Y, Gao W, Ouyang W, Wei J, Wen Z. Epidemiology and outcomes
of complicated skin and soft tissue infections among inpatients in southern
China from 2008 to 2013. PLoS One. 2016;11:e149960.",Staphylococcus aureus,sau,methicillin,SSTI,Li,2016,2008-2013,Cohort,China,61,14,1,AMR,,,mean,sd,5215.21,,,8667.48,2612.64,,,2965.28,0.39,,,,,,"""Complicated Skin and Soft Tissue Infections""",1,15,FALSE,FALSE,FALSE
cassini_157,"Lin MF, Huang ML, Lai SH. Risk factors in the acquisition of extended-spectrum beta-lactamase Klebsiella pneumoniae: a case-control study in a district teaching hospital in Taiwan. The Journal of hospital infection. Jan 2003;53(1):39-45.",Klebsiella pneumoniae,kpn,3g cephalosporins,COL/INF,Lin,2003,"05/01-09/01",Case-control study,Taiwan,43,86,1,AMR,,,mean,range,45,0,143,,18,0,82,,,,,,,,"matching on type of speciment, date of isolation",0,0,FALSE,FALSE,FALSE
cassini_323,"Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Apr 1996;22(4):663-670.",Enterococcus faecium,efa,vancomycin,BSI,Linden,1996,1991 - 1994,Retrospective cohort study,USA,54,48,1,AMR,,,median,pvalue,46,,,,19,,,,0.03,,,,,,matched on Liver transplant patients with VREF or VSEF,0,0,FALSE,FALSE,FALSE
zhen_62,"Lloyd-Smith P, Younger J, Lloyd-Smith E, Green H, Leung V, Romney MG.
Economic analysis of vancomycin-resistant enterococci at a Canadian hospital:
assessing attributable cost and length of stay. J Hosp Infect. 2013;85:54–9.",Enterococcus,efa,vancomycin,COL/INF,Lloyd-Smith,2013,04/2008-03/2009,Retrospective cohort,Canada,217,1075,0,DRI,2009,CAD,excess,95ci,17949,13949,21464,,,,,,,,,,,,"infection & colonisation, control is ""without VRE""",1,81,FALSE,FALSE,FALSE
zhen_62,"Lloyd-Smith P, Younger J, Lloyd-Smith E, Green H, Leung V, Romney MG.
Economic analysis of vancomycin-resistant enterococci at a Canadian hospital:
assessing attributable cost and length of stay. J Hosp Infect. 2013;85:54–9.",Enterococcus,efa,vancomycin,COL/INF,Lloyd-Smith,2013,04/2008-03/2009,Retrospective cohort,Canada,217,1075,1,DRI,,,excess,95ci,13.8,10,16.9,,,,,,,,,,,,"infection & colonisation, control is ""without VRE""",1,81,FALSE,FALSE,FALSE
cassini_317,"Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Apr 1 2002;34(7):922-929.",Enterococcus faecium,efa,vancomycin,BSI,"Lodise",2002,1996-2000,"Retrospective matched case-control",USA,53,53,1,AMR,,,mean,sd,22.7,,,1.88,15.9,,,1.7,,,,,,,"Note from cassini; matched on age, APACHE
score at
onset,
admitting
service, LOS
prior to
onset. LOS after diagnosis",0,0,FALSE,FALSE,FALSE
cassini_180,"Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. Jun 2005;52(2):113-122.",Staphylococcus aureus,sau,methicillin,BSI,Lodise,2005,01/99-01/01,Retrospective cohort study,USA,120,157,1,AMR,,,mean,95ci,19.1,16.4,22.3,,14.2,12.4,16.3,,0.005,,,,,,"Adjusted by APACHE II score at onset of SAB, ICU at onset of SAB, and primary source of SAB.",1,27,FALSE,FALSE,FALSE
zhen_54,"Lodise TP, McKinnon PS. Clinical and economic impact of methicillin
resistance in patients with Staphylococcus aureus bacteremia. Diagn
Microbiol Infect Dis. 2005;52:113–22.",Staphylococcus aureus,sau,methicillin,BSI,Lodise,2005,01/99-01/01,Retrospective cohort study,USA,120,157,0,AMR,2001,USD,mean,95ci,21577,17061,27290,,11668,9550,14223,,0.001,,,,,,"hospital cost after culture, adjusted for APACHE II score at onset of SAB, ICU at the onset of SAB, hospital-acquired SAB, hospital days prior to the onset of SAB, and intravenous drug use source of SAB.",1,27,FALSE,FALSE,FALSE
cassini_155,"Loh LC, Nor Izran Hanim Bt Abdul S, Rosdara Masayuni Bt Mohd S, Raman S, Thayaparan T, Kumar S. Hospital Outcomes of Adult Respiratory Tract Infections with Extended-Spectrum B-Lactamase (ESBL) Producing Klebsiella Pneumoniae. The Malaysian journal of medical sciences : MJMS. Jul 2007;14(2):36-40.",Klebsiella pneumoniae,kpn,3g cephalosporins,RTI,Loh,2006,01/04-12/04,Retrospective cohort study,Malaysia,47,394,1,AMR,,,median,IQR,14,8,32,,5,3,10,,,,,,,,"p<0.001, community + hospital onset cases (hospital duration estimated)",0,0,FALSE,FALSE,FALSE
cassini_112,"Lübbert C, Becker-Rux D, Rodloff AC, Laudi S, Busch T, Bartels M, et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: A case-control analysis. Infection. 2014;42:309–16. ",Klebsiella pneumoniae,kpn,carbapenems,COL/INF,Lübbert ,2014,09/10-09/11,Case-control study,Germany,9,18,1,DRI,,,mean,pvalue,60,,,,32,,,,0.035,,,,,,"liver transplant patients, assumed mean value but no specific definition given, controls were those ""whom carbapenemase-producing pathogens had not been detected""",0,0,FALSE,FALSE,FALSE
cassini_321,"Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. May 1998;26(5):1127-1133.",Enterococcus faecium,efa,vancomycin,BSI,Lucas,1998,1991 - 1996,Case-control,USA,93,101,1,AMR,,,mean,sd,49.1,,,48.3,38.6,,,31.2,,,,,,,matched on 'timing',0,0,FALSE,FALSE,FALSE
naylor_124,"Lucena A, Dalla Costa LM, Nogueira KS, Matos AP, Gales AC, Paganini MC, et al. Nosocomial infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: Molecular epidemiology, risk factors, clinical features and outcomes. Journal of Hospital Infection. Elsevier Ltd; 2014;87:234–40. ",Pseudomonas aeruginosa,pae,MBL,INF,Lucena,2014,01/01-01/08,Cohort,Brazil,58,26,1,AMR,,,mean,range,52,11,108,,41,20,68,,0.23,,,,,,until discharge,0,0,FALSE,FALSE,FALSE
naylor_124,"Lucena A, Dalla Costa LM, Nogueira KS, Matos AP, Gales AC, Paganini MC, et al. Nosocomial infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: Molecular epidemiology, risk factors, clinical features and outcomes. Journal of Hospital Infection. Elsevier Ltd; 2014;87:234–40. ",Pseudomonas aeruginosa,pae,MBL,INF,Lucena,2014,01/01-01/08,Cohort,Brazil,58,26,1,AMR,,,mean,range,37,10,118,,58,14,187,,0.04,,,,,,until death,0,0,FALSE,FALSE,TRUE
cassini_261,"Luyt CE, Aubry A, Lu Q, et al. Imipenem, meropenem or doripenem to treat patients with pseudomonas aeruginosa ventilator-associated pneumonia. American Journal of Respiratory and Critical Care Medicine. 2014;189.",Pseudomonas aeruginosa,pae,carbapenems,RTI,Luyt,2014,18 months,Prospective observational,France,68,101,1,AMR,,,median,IQR,37,23,57,,29,19,46,,,,,,,,"resistance and intermediate combined in case groups, ICU stay",0,0,FALSE,FALSE,FALSE
naylor_125,"Macedo-Viñas M, De Angelis G, Rohner P, Safran E, Stewardson  a., Fankhauser C, et al. Burden of meticillin-resistant Staphylococcus aureus infections at a Swiss University hospital: excess length of stay and costs. Journal of Hospital Infection. 2013;84:132–7. ",Staphylococcus,sau,methicillin,BSI,Macedo-Viñas,2013,01/2009-12/2009,Retrospective cohort,Switzerland,29,25766,1,DRI,,,excess,95ci,20,8,32,,,,,,,,,,,,,0,0,FALSE,FALSE,FALSE
naylor_125,"Macedo-Viñas M, De Angelis G, Rohner P, Safran E, Stewardson  a., Fankhauser C, et al. Burden of meticillin-resistant Staphylococcus aureus infections at a Swiss University hospital: excess length of stay and costs. Journal of Hospital Infection. 2013;84:132–7. ",Staphylococcus,sau,methicillin,SSTI,Macedo-Viñas,2013,01/2009-12/2009,Retrospective cohort,Switzerland,24,25766,1,DRI,,,excess,95ci,18.8,6.1,31.6,,,,,,,,,,,,,0,0,FALSE,FALSE,FALSE
naylor_125,"Macedo-Viñas M, De Angelis G, Rohner P, Safran E, Stewardson  a., Fankhauser C, et al. Burden of meticillin-resistant Staphylococcus aureus infections at a Swiss University hospital: excess length of stay and costs. Journal of Hospital Infection. 2013;84:132–7. ",Staphylococcus,sau,methicillin,SSI,Macedo-Viñas,2013,01/2009-12/2009,Retrospective cohort,Switzerland,36,25766,1,DRI,,,excess,95ci,11.2,2.9,19.5,,,,,,,,,,,,,0,0,FALSE,FALSE,FALSE
naylor_125,"Macedo-Viñas M, De Angelis G, Rohner P, Safran E, Stewardson  a., Fankhauser C, et al. Burden of meticillin-resistant Staphylococcus aureus infections at a Swiss University hospital: excess length of stay and costs. Journal of Hospital Infection. 2013;84:132–7. ",Staphylococcus,sau,methicillin,INF,Macedo-Viñas,2013,01/2009-12/2009,Retrospective cohort,Switzerland,167,25766,1,DRI,,,excess,95ci,11.5,7.9,15,,,,,,,,,,,,all infections,0,0,FALSE,FALSE,FALSE
naylor_125,"Macedo-Viñas M, De Angelis G, Rohner P, Safran E, Stewardson  a., Fankhauser C, et al. Burden of meticillin-resistant Staphylococcus aureus infections at a Swiss University hospital: excess length of stay and costs. Journal of Hospital Infection. 2013;84:132–7. ",Staphylococcus,sau,methicillin,INF,Macedo-Viñas,2013,01/2009-12/2009,Retrospective cohort,Switzerland,78,25766,1,DRI,,,excess,95ci,6.6,2.2,11,,,,,,,,,,,,"all infections apart from BSI, SSI, SSTI",0,0,FALSE,FALSE,FALSE
naylor_126,"MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum ?-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. Journal of Hospital Medicine. 2014;9:232–8. ",Enterobacteriaceae,ent,ESBL,UTI,MacVane,2014,09/11-08/12,Cohort,USA,55,55,0,AMR,2012,USD,median,IQR,10741,6846,15819,,7083,5667,11652,,0.02,,,,,,">= 18 years old, cost loss per person not being included, total hospital cost, includes patients who went on to be bacteraemic (~10%)",1,16,FALSE,FALSE,FALSE
naylor_126,"MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum ?-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. Journal of Hospital Medicine. 2014;9:232–8. ",Enterobacteriaceae,ent,ESBL,UTI,MacVane,2014,09/11-08/12,Cohort,USA,55,55,1,AMR,,,median,IQR,6,4,8,,4,3,6,,0.02,,,,,,">= 18 years old,  includes patients who went on to be bacteraemic (~10%)",1,16,FALSE,FALSE,FALSE
naylor_126,"MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum ?-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. Journal of Hospital Medicine. 2014;9:232–8. ",Enterobacteriaceae,ent,ESBL,BSI,MacVane,2014,09/11-08/12,Cohort,USA,7,5,1,AMR,,,median,pvalue,11,,,,5,,,,0.05,,,,,,bacteraemia from UTI,1,104,FALSE,FALSE,FALSE
naylor_126,"MacVane SH, Tuttle LO, Nicolau DP. Impact of extended-spectrum ?-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. Journal of Hospital Medicine. 2014;9:232–8. ",Enterobacteriaceae,ent,ESBL,BSI,MacVane,2014,09/11-08/12,Cohort,USA,7,5,0,AMR,2012,USD,median,pvalue,27671,,,,5898,,,,0.03,,,,,,bacteraemia from UTI,1,104,FALSE,FALSE,FALSE
cassini_323,"Mainous MR, Lipsett PA, O'Brien M. Enterococcal bacteremia in the surgical intensive care unit. Does vancomycin resistance affect mortality? The Johns Hopkins SICU Study Group. Arch Surg. Jan 1997;132(1):76-81.",Enterococcus faecium,efa,vancomycin,BSI,Mainous,1997,1992-1994,Retrospective cohort study,USA,10,31,1,AMR,,,mean,sd,28,,,18,12,,,10,,,,,,,Matched on stay in SICU,0,0,FALSE,FALSE,FALSE
zhen_73,"Maslikowska JA, Walker SAN, Elligsen M, Mittmann N, Palmay L, Daneman N,
et al. Impact of infection with extended-spectrum beta-lactamaseproducing
Escherichia coli or Klebsiella species on outcome and
hospitalization costs. J Hosp Infect. 2016;92:33–41.",Enterobacteriaceae,ent,ESBL,INF,Maslikowska,2016,06/2010 - 04/2013,Case-control,Canada,75,75,0,AMR,2013,CAD,median,range,10507,1260,427156,,7882,441,58748,,0.0391,,,,,,"adults, breakdown of infection type in desc",1,34,FALSE,FALSE,FALSE
zhen_73,"Maslikowska JA, Walker SAN, Elligsen M, Mittmann N, Palmay L, Daneman N,
et al. Impact of infection with extended-spectrum beta-lactamaseproducing
Escherichia coli or Klebsiella species on outcome and
hospitalization costs. J Hosp Infect. 2016;92:33–41.",Enterobacteriaceae,ent,ESBL,INF,Maslikowska,2016,06/2010 - 04/2013,Case-control,Canada,75,75,1,AMR,,,median,range,8,0.5,84,,6,0.5,91,,0.0236,,,,,,"adults, breakdown of infection type in desc",1,34,FALSE,FALSE,FALSE
Zhen_39,"McHugh CG, Riley LW. Risk factors and costs associated with methicillinresistant
Staphylococcus aureus bloodstream infections. Infect Control Hosp
Epidemiol. 2004;25:425–30.",Staphylococcus aureus,sau,methicillin,BSI,McHugh,2004,01/1997-12/1999,Restrospective case-control,USA,20,60,0,AMR,2015,USD,mean,pvalue,65320,,,,13797,,,,0.0003,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_209,"McMaster J, Booth MG, Smith A, Hamilton K. Meticillin-resistant Staphylococcus aureus in the intensive care unit: its effect on outcome and risk factors for acquisition. The Journal of hospital infection. Aug 2015;90(4):327-332.",Staphylococcus,sau,methicillin,BSI,McMaster,2015,04/07-11/13,Prospective study,United Kingdom,58,174,1,DRI,,,median,range,16.1,1.5,124.1,,16.9,1.9,92.1,,,,,,,,ICU patients,0,0,FALSE,FALSE,TRUE
cassini_220,"McMullan BJ, Bowen A, Blyth CC, et al. Epidemiology and mortality of staphylococcus aureus Bacteremia in Australian and New Zealand children. JAMA pediatrics. 2016;170(10):979-986.",Staphylococcus aureus,sau,methicillin,BSI,McMullan,2016,01/07-12/12,Prospective cohort,Australia & New Zeland,142,931,1,AMR,,,median,IQR,17,8,38,,14,7,33,,,,,,,,"patients were children, matched on age",0,0,FALSE,FALSE,FALSE
cassini_85,"Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. The Journal of infection. Sep 2007;55(3):254-259.",Escherichia coli,eco,3g cephalosporins,BSI,Melzer,2007,06/03-11/05,Retrospective cohort study,United Kingdom,46,308,1,AMR,,,median,pvalue,9,,,,12,,,,0.11,,,,,,survivors,0,0,FALSE,FALSE,TRUE
cassini_85,"Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. The Journal of infection. Sep 2007;55(3):254-259.",Escherichia coli,eco,3g cephalosporins,BSI,Melzer,2007,06/03-11/05,Retrospective cohort study,United Kingdom,46,308,1,AMR,,,median,pvalue,7,,,,5,,,,0.69,,,,,,non-survivors,0,0,FALSE,FALSE,FALSE
naylor_136,"Miller TTL, Cirule A, Wilson F a FF a, Holtz TH, Riekstina V, Cain KP, et al. The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia. Cost effectiveness and resource allocation?: C/E. 2013;11:9. ",Tuberculosis,tb,MDR,RTI,Miller,2013,2002,Cohort,Latvia,92,54,1,AMR,,,mean,95ci,475.3,427.9,522.6,,110.2,86.1,134.4,,,,,,,,"note p<0.001, all adults, adjusted hospital days",1,53,FALSE,FALSE,FALSE
naylor_136,"Miller TTL, Cirule A, Wilson F a FF a, Holtz TH, Riekstina V, Cain KP, et al. The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia. Cost effectiveness and resource allocation?: C/E. 2013;11:9. ",Tuberculosis,tb,MDR,RTI,Miller,2013,2002,Cohort,Latvia,92,54,0,AMR,2002,USD,excess,95ci,18729,15563,21893,,,,,,,,,,,,"note p<0.001, all adults, inpatient costs",1,53,FALSE,FALSE,FALSE
cassini_249,"Mínguez S, Molinos S, Mateo L, et al. Septic arthritis due to methylcyllin-resistant Staphylococcus aureus in adults. Reumatologia Clinica. 2015;11(6):381-386.",Staphylococcus aureus,sau,methicillin,J,Minguez,2015,1984-2011,Retrospective study,Mexico,7,17,1,AMR,,,mean,pvalue,33,,,,20,,,,0.361,,,,,,all patients had septic arthritis due to S. aureus,0,0,FALSE,FALSE,FALSE
cassini_148,"Mosqueda-Gomez JL, Montano-Loza A, Rolon AL, et al. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Nov 2008;12(6):653-659",Klebsiella pneumoniae,kpn,3g cephalosporins,BSI,Mosqueda-Gomez,2008,01/93-12/02,Retrospective case-control study,Mexico,17,104,1,AMR,,,mean,pvalue,20.9,,,,15.9,,,,0.49,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_16,"Nazer LH, Kharabsheh A, Rimawi D, Mubarak S, Hawari F. Characteristics and Outcomes of Acinetobacter baumannii Infections in Critically Ill Patients with Cancer: A Matched Case-Control Study. Microbial drug resistance (Larchmont, N.Y.). Oct 2015;21(5):556-561.",Acinetobacter baumannii,aba,carbapenems,INF,Nazer,2015,01/10-12/13,Matched case-control study,Jordan,142,232,1,DRI,,,median,IQR,12,6,13,,3,1,7,,,,,,,,"critically ill cancer patients, ICU stay, gives counts of source",0,0,FALSE,FALSE,FALSE
founou_55,"Ndir A, Diop A, Ka R, Faye PM, Dia-Badiane NM, Ndoye B, et al. Infections caused by extended-spectrum
beta-lactamases producing Enterobacteriaceae: clinical and economic impact in patients hospitalized
in 2 teaching hospitals in Dakar, Senegal. Antimicrob Resist Infect Control. 2016; 5:13. https://doi.
org/10.1186/s13756-016-0114-7 PMID: 27096085",Enterobacteriaceae,ent,ESBL,INF,Ndir A,2016,04/2012-10/2012,Cohort,Senegal,110,76,0,AMR,2012,EUR,excess,95ci,100,78,125,,,,,,,,,,,,,1,17,FALSE,FALSE,FALSE
founou_55,"Ndir A, Diop A, Ka R, Faye PM, Dia-Badiane NM, Ndoye B, et al. Infections caused by extended-spectrum
beta-lactamases producing Enterobacteriaceae: clinical and economic impact in patients hospitalized
in 2 teaching hospitals in Dakar, Senegal. Antimicrob Resist Infect Control. 2016; 5:13. https://doi.
org/10.1186/s13756-016-0114-7 PMID: 27096085",Enterobacteriaceae,ent,ESBL,INF,Ndir A,2016,04/2012-10/2012,Cohort,Senegal,110,76,1,AMR,,,excess,95ci,4,3.8,4.6,,,,,,,,,,,,,1,17,FALSE,FALSE,FALSE
founou_55,"Ndir A, Diop A, Ka R, Faye PM, Dia-Badiane NM, Ndoye B, et al. Infections caused by extended-spectrum
beta-lactamases producing Enterobacteriaceae: clinical and economic impact in patients hospitalized
in 2 teaching hospitals in Dakar, Senegal. Antimicrob Resist Infect Control. 2016; 5:13. https://doi.
org/10.1186/s13756-016-0114-7 PMID: 27096085",Enterobacteriaceae,ent,ESBL,INF,Ndir A,2016,04/2012-10/2012,Cohort,Senegal,110,186,1,DRI,,,excess,95ci,7.9,7.6,9.2,,,,,,,,,,,,,0,0,FALSE,FALSE,FALSE
wozniak_26,"Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of
healthcare- and community-associated infections with antimicrobialresistant
versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;
55(6):807–15.",Staphylococcus aureus,sau,oxacillin,INF,Neidell,2012,2006-2008,Retrospective cohort study,USA,318,353,1,AMR,,,excess,95ci,0.42,-2.29,3.13,,,,,,,,,,,,"healthcare associated infections, censored models",1,49,FALSE,FALSE,FALSE
wozniak_26,"Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of
healthcare- and community-associated infections with antimicrobialresistant
versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;
55(6):807–15.",Staphylococcus aureus,sau,oxacillin,INF,Neidell,2012,2006-2008,Retrospective cohort study,USA,318,353,0,AMR,2008,USD,excess,95ci,-16000,-36900,4800,,,,,,,,,,,,"healthcare associated infections, censored models",1,49,FALSE,FALSE,TRUE
wozniak_26,"Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of
healthcare- and community-associated infections with antimicrobialresistant
versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;
55(6):807–15.",Klebsiella pneumoniae,kpn,carbapenems,INF,Neidell,2012,2006-2008,Retrospective cohort study,USA,173,744,1,AMR,,,excess,95ci,1.63,-0.96,4.21,,,,,,,,,,,,"healthcare associated infections, censored models",1,50,FALSE,FALSE,FALSE
wozniak_26,"Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of
healthcare- and community-associated infections with antimicrobialresistant
versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;
55(6):807–15.",Klebsiella pneumoniae,kpn,carbapenems,INF,Neidell,2012,2006-2008,Retrospective cohort study,USA,173,744,0,AMR,2008,USD,excess,95ci,13200,-5900,32200,,,,,,,,,,,,"healthcare associated infections, censored models",1,50,FALSE,FALSE,FALSE
wozniak_26,"Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of
healthcare- and community-associated infections with antimicrobialresistant
versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;
55(6):807–15.",Enterococcus faecium,efa,vancomycin,INF,Neidell,2012,2006-2008,Retrospective cohort study,USA,561,709,1,AMR,,,excess,95ci,0.85,-0.86,2.55,,,,,,,,,,,,"healthcare associated infections, censored models",1,51,FALSE,FALSE,FALSE
wozniak_26,"Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of
healthcare- and community-associated infections with antimicrobialresistant
versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;
55(6):807–15.",Enterococcus faecium,efa,vancomycin,INF,Neidell,2012,2006-2008,Retrospective cohort study,USA,561,709,0,AMR,2008,USD,excess,95ci,16900,4600,29300,,,,,,,,,,,,"healthcare associated infections, censored models",1,51,FALSE,FALSE,FALSE
wozniak_26,"Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of
healthcare- and community-associated infections with antimicrobialresistant
versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;
55(6):807–15.",Staphylococcus aureus,sau,oxacillin,INF,Neidell,2012,2006-2008,Retrospective cohort study,USA,240,295,1,AMR,,,excess,95ci,0.07,-2.77,2.91,,,,,,,,,,,,"community associated infections, censored models",1,61,FALSE,FALSE,FALSE
wozniak_26,"Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of
healthcare- and community-associated infections with antimicrobialresistant
versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;
55(6):807–15.",Staphylococcus aureus,sau,oxacillin,INF,Neidell,2012,2006-2008,Retrospective cohort study,USA,240,295,0,AMR,2008,USD,excess,95ci,7700,-17400,32800,,,,,,,,,,,,"community associated infections, censored models",1,61,FALSE,FALSE,FALSE
wozniak_26,"Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of
healthcare- and community-associated infections with antimicrobialresistant
versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;
55(6):807–15.",Klebsiella pneumoniae,kpn,carbapenems,INF,Neidell,2012,2006-2008,Retrospective cohort study,USA,137,583,1,AMR,,,excess,95ci,2.34,-0.55,5.22,,,,,,,,,,,,"community associated infections, censored models",1,62,FALSE,FALSE,FALSE
wozniak_26,"Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of
healthcare- and community-associated infections with antimicrobialresistant
versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;
55(6):807–15.",Klebsiella pneumoniae,kpn,carbapenems,INF,Neidell,2012,2006-2008,Retrospective cohort study,USA,137,583,0,AMR,2008,USD,excess,95ci,11.8,-10.5,34.2,,,,,,,,,,,,"community associated infections, censored models",1,62,FALSE,FALSE,FALSE
wozniak_26,"Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of
healthcare- and community-associated infections with antimicrobialresistant
versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;
55(6):807–15.",Enterococcus faecium,efa,vancomycin,INF,Neidell,2012,2006-2008,Retrospective cohort study,USA,92,429,1,AMR,,,excess,95ci,8.86,5.72,11.99,,,,,,,,,,,,"community associated infections, censored models",1,63,FALSE,FALSE,FALSE
wozniak_26,"Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of
healthcare- and community-associated infections with antimicrobialresistant
versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;
55(6):807–15.",Enterococcus faecium,efa,vancomycin,INF,Neidell,2012,2006-2008,Retrospective cohort study,USA,92,429,0,AMR,2008,USD,excess,95ci,80.8,54.9,106.7,,,,,,,,,,,,"community associated infections, censored models",1,63,FALSE,FALSE,FALSE
zhen_50,"Nelson RE, Samore MH, Jones M, Greene T, Stevens VW, Liu CF, et al.
Reducing time-dependent bias in estimates of the attributable cost of
health care-associated methicillin-resistant Staphylococcus aureus infections:
a comparison of three estimation strategies. Med Care. 2015;53:827–34.",Staphylococcus aureus,sau,methicillin,INF,Nelson,2015,10/2007-12/2012,Retrospective cohort study,USA,3982,382812,0,DRI,2010,USD,excess,95ci,31570,30074,33067,,,,,,,,,,,,conventional methods,1,75,FALSE,FALSE,FALSE
zhen_50,"Nelson RE, Samore MH, Jones M, Greene T, Stevens VW, Liu CF, et al.
Reducing time-dependent bias in estimates of the attributable cost of
health care-associated methicillin-resistant Staphylococcus aureus infections:
a comparison of three estimation strategies. Med Care. 2015;53:827–34.",Staphylococcus aureus,sau,methicillin,INF,Nelson,2015,10/2007-12/2012,Retrospective cohort study,USA,3982,382812,1,DRI,,,excess,95ci,17.64,17.58,17.71,,,,,,,,,,,,,1,75,FALSE,FALSE,FALSE
zhen_50,"Nelson RE, Samore MH, Jones M, Greene T, Stevens VW, Liu CF, et al.
Reducing time-dependent bias in estimates of the attributable cost of
health care-associated methicillin-resistant Staphylococcus aureus infections:
a comparison of three estimation strategies. Med Care. 2015;53:827–34.",Staphylococcus aureus,sau,methicillin,INF,Nelson,2015,10/2007-12/2012,Retrospective cohort study,USA,92,121428,0,DRI,2010,USD,excess,95ci,24015,10882,37149,,,,,,,,,,,,post-infection methods,1,76,FALSE,FALSE,FALSE
zhen_50,"Nelson RE, Samore MH, Jones M, Greene T, Stevens VW, Liu CF, et al.
Reducing time-dependent bias in estimates of the attributable cost of
health care-associated methicillin-resistant Staphylococcus aureus infections:
a comparison of three estimation strategies. Med Care. 2015;53:827–34.",Staphylococcus aureus,sau,methicillin,INF,Nelson,2015,10/2007-12/2012,Retrospective cohort study,USA,92,121428,1,DRI,,,excess,95ci,11.43,10.44,12.43,,,,,,,,,,,,,1,76,FALSE,FALSE,FALSE
zhen_50,"Nelson RE, Samore MH, Jones M, Greene T, Stevens VW, Liu CF, et al.
Reducing time-dependent bias in estimates of the attributable cost of
health care-associated methicillin-resistant Staphylococcus aureus infections:
a comparison of three estimation strategies. Med Care. 2015;53:827–34.",Staphylococcus aureus,sau,methicillin,INF,Nelson,2015,10/2007-12/2012,Retrospective cohort study,USA,2917,10457,0,DRI,2010,USD,excess,95ci,26855,22583,31126,,,,,,,,,,,,matched-analysis,1,77,FALSE,FALSE,FALSE
zhen_50,"Nelson RE, Samore MH, Jones M, Greene T, Stevens VW, Liu CF, et al.
Reducing time-dependent bias in estimates of the attributable cost of
health care-associated methicillin-resistant Staphylococcus aureus infections:
a comparison of three estimation strategies. Med Care. 2015;53:827–34.",Staphylococcus aureus,sau,methicillin,INF,Nelson,2015,10/2007-12/2012,Retrospective cohort study,USA,2917,10457,1,DRI,,,excess,95ci,13.97,10.49,17.44,,,,,,,,,,,,,1,77,FALSE,FALSE,FALSE
naylor_143,"Nouvenne A, Ticinesi A, Lauretani F, Maggio M, Lippi G, Guida L, et al. Comorbidities and disease severity as risk factors for Carbapenem-Resistant klebsiella pneumoniae colonization: Report of an experience in an internal medicine unit. PLoS ONE. 2014;9:1–8. ",Klebsiella pnuemonaie,kpn,carbapenems,COL/INF,Nouvenne,2014,08/2011-05/2012,Case-control,Italy,133,400,1,DRI,,,mean,sd,35,,,24,18,,,12,,,,,,,"p<0.0001, elderly and frail patients",0,0,FALSE,FALSE,FALSE
naylor_146,"Oliveira MC, Oliveira CRA, Gonçalves KV, Santos MS, Tardelli ACS, Nobre VA. Enterobacteriaceae resistant to third generation cephalosporins upon hospital admission: Risk factors and clinical outcomes. Brazilian Journal of Infectious Diseases. 2015;19:239–45. ",Enterobacteriaceae,ent,3g cephalosporins,INF,Oliveira,2015,08/11-07/12,Cohort,Brazil,62,124,1,AMR,,,median,IQR,13,4.75,31,,5,1.25,9.75,,,,,,,,>=18 years old,0,0,FALSE,FALSE,FALSE
naylor_150,"Ostermann H, Blasi, Medina J, Pascual E, McBride K, Garau J. Resource use in patients hospitalized with complicated skin and soft tissue infections in Europe and analysis of vulnerable groups?: the REACH study. J Med Econ. 2014;17:719–29. ",Staphylococcus aureus,sau,methicillin,SSTI,Ostermann,2014,2010-2011,Cohort,Europe,102,274,1,AMR,,,mean,sd,27.7,,,23.9,18.4,,,19.9,,,,,,,">= 18 years old, complicated skin and soft tissue infections",0,0,FALSE,FALSE,FALSE
naylor_151,"Osthoff M, McGuinness SL, Wagen AZ, Eisen DP. Urinary tract infections due to extended-spectrum beta-lactamase-producing Gram-negative bacteria: identification of risk factors and outcome predictors in an Australian tertiary referral hospital. International journal of infectious diseases?: IJID?: official publication of the International Society for Infectious Diseases. International Society for Infectious Diseases; 2015;34:79–83. ",Gram-negative,gn,ESBL,UTI,Osthoff,2015,01/03-12/09,Cohort,Australia,100,100,1,AMR,,,median,IQR,6,2,16,,2,0,9,,0.002,,,,,,>=18 years old,0,0,FALSE,FALSE,FALSE
zhen_37,"Ott E, Bange FC, Reichardt C, Graf K, Eckstein M, Schwab F, et al. Costs of
nosocomial pneumonia caused by methicillin-resistant Staphylococcus
aureus. J Hosp Infect. 2010;76:300–3.",Staphylococcus aureus,sau,methicillin,RTI,Ott,2010,01/2005-12/2007,Cohort,Germany,41,41,0,AMR,2007,EUR,median,IQR,60684,23127,93468,,38732,15365,47814,,0.011,,,,,,Pneumonia,1,18,FALSE,FALSE,FALSE
zhen_37,"Ott E, Bange FC, Reichardt C, Graf K, Eckstein M, Schwab F, et al. Costs of
nosocomial pneumonia caused by methicillin-resistant Staphylococcus
aureus. J Hosp Infect. 2010;76:300–3.",Staphylococcus aureus,sau,methicillin,RTI,Ott,2010,01/2005-12/2007,Cohort,Germany,41,41,1,AMR,,,median,IQR,32,21.5,55.5,,28,15,43.5,,0.021,,,,,,Pneumonia,1,18,FALSE,FALSE,FALSE
zhen_33,"Park SY, Son JS, Oh IH, Choi JM, Lee MS. Clinical impact of methicillinresistant
Staphylococcus aureus bacteremia based on propensity scores.
Infection. 2011;39:141–7.",Staphylococcus aureus,sau,methicillin,BSI,Park,2011,01/2003-12/2008.,Cohort,South Korea,145,121,0,AMR,2008,USD,mean,sd,9369,,,12911,8355.8,,,8959,0.62,,,,,,,1,19,FALSE,FALSE,FALSE
zhen_33,"Park SY, Son JS, Oh IH, Choi JM, Lee MS. Clinical impact of methicillinresistant
Staphylococcus aureus bacteremia based on propensity scores.
Infection. 2011;39:141–7.",Staphylococcus aureus,sau,methicillin,BSI,Park,2011,01/2003-12/2008.,Cohort,South Korea,145,121,1,AMR,,,mean,sd,59.9,,,67.1,34.8,,,33.8,0.01,,,,,,,1,19,FALSE,FALSE,FALSE
naylor_159,"Patel TS, Nagel JL. Clinical outcomes of enterobacteriaceae infections stratified by carbapenem MICs. Journal of Clinical Microbiology. 2015;53:201–5. ",Enterobacteriaceae,ent,carbapenems,INF,Patel,2015,01/2009-08/2013,Cohort,USA,18,18,1,AMR,,,mean,sd,57.6,,,45,34.4,,,25,0.06,,,,,,"adults, MIC <=1 vs MIC of 2 - 8mg mg/liter",0,0,FALSE,FALSE,FALSE
naylor_160,"Pau CKY, Ma FFT, Ip M, You JHS. Characteristics and outcomes of Klebsiella pneumoniae bacteraemia in Hong Kong. Infectious Diseases. 2015;47:283–8. ",Klebsiella pneumoniae,kpn,ESBL,BSI,Pau,2015,06/09-12/11,Cohort,Hong Kong,32,176,0,AMR,2014,USD,mean,sd,16026,,,20643,11602,,,71859,0.38,,,,,,,0,0,FALSE,FALSE,FALSE
zhen_71,"Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, et al. Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Medicine. 2002; 28:692-7.",Enterococcus,efa,vancomycin,INF,Pelz,2002,3 months 1996,Prospective cohort,US,6,89,0,DRI,1996,USD,excess_median,95ci,33251,20182,46320,,,,,,,,,,,,"ICU, after comparison of non-infected",0,0,FALSE,FALSE,FALSE
zhen_71,"Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, et al. Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Medicine. 2002; 28:692-7.",Enterococcus,efa,vancomycin,INF,Pelz,2002,3 months 1996,Prospective cohort,US,6,16,1,AMR,,,median,pvalue,57,,,,52,,,,0.8,,,,,,hospital,0,0,FALSE,FALSE,FALSE
zhen_71,"Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, et al. Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Medicine. 2002; 28:692-7.",Enterococcus,efa,vancomycin,INF,Pelz,2002,3 months 1996,Prospective cohort,US,6,16,0,AMR,1996,USD,median,95ci,33251,20182,46320,,21914,11779,32048,,,,,,,,ICU,1,97,FALSE,FALSE,FALSE
zhen_71,"Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, et al. Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Medicine. 2002; 28:692-7.",Enterococcus,efa,vancomycin,INF,Pelz,2002,3 months 1996,Prospective cohort,US,6,16,1,AMR,,,median,pvalue,14,,,,17.5,,,,0.63,,,,,,ICU,1,97,FALSE,FALSE,TRUE
zhen_71,"Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, et al. Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Medicine. 2002; 28:692-7.",Enterococcus,efa,vancomycin,INF,Pelz,2002,3 months 1996,Prospective cohort,USA,6,83,0,DRI,1996,USD,median,pvalue,33224,,,,18863,,,,0.03,,,,,,"ICU, gives count breakdown of source",0,0,FALSE,FALSE,FALSE
cassini_117,"Pereira MR, Scully BF, Pouch SM, et al. Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. Dec 2015;21(12):1511-1519.",Klebsiella pneumoniae,kpn,carbapenems,INF,Pereira,2015,01/10-01/13,Retrospective cohort study,USA,20,248,1,DRI,,,median,range,40,23,82,,12,9,21,,,,,,,,"patients are liver transplant recipients, p<0.0001",0,0,FALSE,FALSE,FALSE
cassini_318,"Peset V, Tallon P, Sola C, et al. Epidemiological, microbiological, clinical, and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. Oct 2000;19(10):742-749.",Enterococcus faecium,efa,vancomycin,BSI,"Peset",2000,"1994-1996","Prospective case-control",Spain,17,169,1,AMR,,,mean,sd,74.75,,,46.27,47.26,,,37.59,,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_109,"Pouch SM, Kubin CJ, Satlin MJ, et al. Epidemiology and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteriuria in kidney transplant recipients. Transplant Infectious Disease. 2015;17(6):800-809.",Klebsiella pneumoniae,kpn,carbapenems,UTI,Pouch,2015,01/07-12/10,Case-control,USA,20,252,1,AMR,,,median,IQR,17,9,43,,7,5,10,,,,,,,,patients are kidney transplant recipients,0,0,FALSE,FALSE,FALSE
zhen_69,"Puchter L, Chaberny IF, Schwab F, Vonberg RP, Bange FC, Ebadi E.
Economic burden of nosocomial infections caused by vancomycin-resistant
enterococci. Antimicrob Resist Infect Control. 2018;7:1.",Enterococcus,efa,vancomycin,INF,Putcher,2018,01/2005-12/2008,Cohort,Germany,42,42,0,AMR,2008,EUR,excess_median,IQR,13157,-16420,74593,,,,,,0.036,,,,,,"after infection, ""we only considered patients with
surgical site infection (SSI), blood stream infection (BSI),
intraabdominal infections and infections of organs
within visceral cavity due to VRE.""",1,33,FALSE,FALSE,FALSE
zhen_69,"Puchter L, Chaberny IF, Schwab F, Vonberg RP, Bange FC, Ebadi E.
Economic burden of nosocomial infections caused by vancomycin-resistant
enterococci. Antimicrob Resist Infect Control. 2018;7:1.",Enterococcus,efa,vancomycin,INF,Putcher,2018,01/2005-12/2008,Cohort,Germany,42,42,1,AMR,,,median,IQR,33,13,63,,27,14,35,,0.122,,,,,,"after infection, ""we only considered patients with
surgical site infection (SSI), blood stream infection (BSI),
intraabdominal infections and infections of organs
within visceral cavity due to VRE.""",1,33,FALSE,FALSE,FALSE
cassini_298,"Reechaipichitkul W, Assawasanti K, Chaimanee P. Risk factors and clinical outcomes of penicillin resistant S. pneumoniae community-acquired pneumonia in Khon Kaen, Thailand. The Southeast Asian journal of tropical medicine and public health. Mar 2006;37(2):320-326.",Streptococcus pneumoniae,spn,penicillins,RTI,Reechaipichitkul,2006,01/95-12/04,Cross-sectional study,Thailand,22,42,1,AMR,,,mean,sd,12.2,,,9,15.5,,,17.8,0.43,,,,,,,0,0,FALSE,FALSE,TRUE
zhen_42,"Reed SD, Friedman JY, Engemann JJ, Griffiths RI, Anstrom KJ, Kaye KS, et al.
Costs and outcomes among hemodialysis-dependent patients with
methicillin-resistant or methicillin-susceptible Staphylococcus aureus
bacteremia. Infect Control Hosp Epidemiol. 2005;26:175–83.",Staphylococcus aureus,sau,methicillin,BSI,Reed,2005,07/1996 and 08/2001,Cohort,USA,54,89,0,AMR,2001,USD,mean,sd,28297,,,23619,16066,,,16337,0.0001,,,,,,Hemodialysis patients,1,20,FALSE,FALSE,FALSE
zhen_42,"Reed SD, Friedman JY, Engemann JJ, Griffiths RI, Anstrom KJ, Kaye KS, et al.
Costs and outcomes among hemodialysis-dependent patients with
methicillin-resistant or methicillin-susceptible Staphylococcus aureus
bacteremia. Infect Control Hosp Epidemiol. 2005;26:175–83.",Staphylococcus aureus,sau,methicillin,BSI,Reed,2005,07/1996 and 08/2001,Cohort,USA,54,89,1,AMR,,,mean,sd,16.6,,,12.7,9.3,,,8.5,0.0001,,,,,,Hemodialysis patients,1,20,FALSE,FALSE,FALSE
zhen_49,"Resch A, Wilke M, Fink C. The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals. The European Journal of Health Economics. 2009 Jul 1;10(3):287-97.",Staphylococcus aureus,sau,methicillin,COL/INF,Resch,2009,2004,Retrospective matched cohort,Germany,1026,1026,1,AMR,,,excess,sd,11,,,25,,,,,,,,,,,matching pairs 1,1,58,FALSE,FALSE,FALSE
zhen_49,"Resch A, Wilke M, Fink C. The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals. The European Journal of Health Economics. 2009 Jul 1;10(3):287-97.",Staphylococcus aureus,sau,methicillin,COL/INF,Resch,2009,2004,Retrospective matched cohort,Germany,1026,1026,0,AMR,2008,EUR,excess,sd,8198,,,19403,,,,,,,,,,,matching pairs 1,1,58,FALSE,FALSE,FALSE
zhen_49,"Resch A, Wilke M, Fink C. The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals. The European Journal of Health Economics. 2009 Jul 1;10(3):287-97.",Staphylococcus aureus,sau,methicillin,COL/INF,Resch,2009,2004,Retrospective matched cohort,Germany,549,549,1,AMR,,,excess,sd,11,,,23,,,,,,,,,,,matching pairs 2,1,59,FALSE,FALSE,FALSE
zhen_49,"Resch A, Wilke M, Fink C. The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals. The European Journal of Health Economics. 2009 Jul 1;10(3):287-97.",Staphylococcus aureus,sau,methicillin,COL/INF,Resch,2009,2004,Retrospective matched cohort,Germany,549,549,0,AMR,2008,EUR,excess,sd,7257,,,17572,,,,,,,,,,,matching pairs 2,1,59,FALSE,FALSE,FALSE
cassini_172,"Romero-Vivas J, Rubio M, Fernandez C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Dec 1995;21(6):1417-1423.",Staphylococcus aureus,sau,methicillin,BSI,Romero-Vivas,1995,01/90-11/93,Prospective cohort,Spain,84,100,1,AMR,,,mean,sd,39.53,,,32.93,63.5,,,99.8,0.02,,,,,,,0,0,FALSE,FALSE,TRUE
cassini_9,"Routsi C, Pratikaki M, Platsouka E, et al. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection. Jun 2010;38(3):173-180.",Acinetobacter baumannii,aba,carbapenems,BSI,Routsi,2010,09/04-01/06,Prospective observational,Greece,30,66,1,AMR,,,median,IQR,33,18.8,55.8,,28.5,14.5,51,,,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_171,"Rubio-Terres C, Garau J, Grau S, Martinez-Martinez L, Cast of Resistance Study g. Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. Jun 2010;16(6):722-728.",Staphylococcus aureus,sau,methicillin,BSI,Rubio-Terres,2009,01/05-12/05,Multicentre retrospective,Spain,121,245,1,AMR,,,mean,95ci,24.88,19.9,29.9,,22.66,18.8,26.5,,,,,,,,,0,0,FALSE,FALSE,FALSE
zhen_41,"Rubio-Terres C, Garau J, Grau S, Martinez-Martinez L. Cost of bacteraemia
caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus
in Spain: a retrospective cohort study. Clin Microbiol Infect. 2010;16:722–8.",Staphylococcus aureus,sau,methicillin,BSI,Rubio-Terres,2009,01/05-12/05,Multicentre retrospective,Spain,121,245,0,AMR,2006,EUR,excess_median,range,1205.34,293,2847.14,,,,,,,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_194,"Salgado CD, Dash S, Cantey JR, Marculescu CE. Higher risk of failure of methicillin-resistant Staphylococcus aureus prosthetic joint infections. Clin Orthop Relat Res. Aug 2007;461:48-53",Staphylococcus aureus,sau,methicillin,J,Salgado,2007,01/95-12/04,Retrospective cohort study,USA,31,12,1,AMR,,,median,range,15,5,33,,10,4,40,,0.01,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_247,"Self WH, Wunderink RG, Williams DJ, et al. Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes. Clinical Infectious Diseases. 2016;63(3):300-309.",Staphylococcus aureus,sau,methicillin,RTI,Self,2016,"2,5 years",Prospective study,Australia,15,22,1,AMR,,,median,IQR,9,8,13,,6,4,10,,,,,,,,all patients had CA-pneumonia,0,0,FALSE,FALSE,FALSE
cassini_23,"Sheng WH, Liao CH, Lauderdale TL, et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Sep 2010;14(9):e764-769.",Acinetobacter baumannii,aba,carbapenems,COL,Sheng,2010,05/04-11/06,Multicentre retrospective,Taiwan,30,30,1,AMR,,,median,range,41,5,282,,29,2,227,,0.03,,,,,,"colonised, has source by counts",0,0,FALSE,FALSE,FALSE
cassini_23,"Sheng WH, Liao CH, Lauderdale TL, et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Sep 2010;14(9):e764-769.",Acinetobacter baumannii,aba,carbapenems,INF,Sheng,2010,05/04-11/06,Multicentre retrospective,Taiwan,91,97,1,AMR,,,median,range,37,1,218,,23,1,151,,0.009,,,,,,"infected, has source by counts",0,0,FALSE,FALSE,FALSE
cassini_23,"Sheng WH, Liao CH, Lauderdale TL, et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Sep 2010;14(9):e764-769.",Acinetobacter baumannii,aba,carbapenems,BSI,Sheng,2010,05/04-11/06,Multicentre retrospective,Taiwan,63,60,1,AMR,,,median,range,36,1,218,,19,1,151,,0.005,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_110,"Shilo S, Assous MV, Lachish T, et al. Risk factors for bacteriuria with carbapenem-resistant Klebsiella pneumoniae and its impact on mortality: A case-control study. Infection. 2013;41(2):503-509.",Klebsiella pneumoniae,kpn,carbapenems,UTI,Shilo,2013,01/06-04/09,Case-control study,Israel,135,127,1,AMR,,,mean,sd,28,,,33,22,,,28,,,,,,,,0,0,FALSE,FALSE,FALSE
zhen_28,"Shorr AF, Haque N, Taneja C, Zervos M, Lamerato L, Kothari S, et al. Clinical
and economic outcomes for patients with health care-associated
Staphylococcus aureus pneumonia. J Clin Microbiol. 2010;48:3258–62.",Staphylococcus aureus,sau,methicillin,RTI,Shorr,2010,01/2005-05/2008,Cohort,USA,87,55,0,AMR,2008,USD,mean,sd,98170,,,94707,104121,,,91314,0.712,,,,,,healthcare associated,1,105,FALSE,FALSE,TRUE
zhen_28,"Shorr AF, Haque N, Taneja C, Zervos M, Lamerato L, Kothari S, et al. Clinical
and economic outcomes for patients with health care-associated
Staphylococcus aureus pneumonia. J Clin Microbiol. 2010;48:3258–62.",Staphylococcus aureus,sau,methicillin,RTI,Shorr,2010,01/2005-05/2008,Cohort,USA,87,55,1,AMR,,,mead,sd,14,,,11.2,14,,,9.1,,,,,,,healthcare associated,1,105,FALSE,FALSE,FALSE
zhen_30,"Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH. Morbidity and
cost burden of methicillin-resistant Staphylococcus aureus in early onset
ventilator-associated pneumonia. Crit care (London, England). 2006;10:R97.",Staphylococcus aureus,sau,methicillin,RTI,Shorr,2006,01/2002-12/2003,Cohort,USA,59,95,0,AMR,2003,USD,median,IQR,40734,18347,71064,,36523,15539,72080,,0.3,,,,,,,1,21,FALSE,FALSE,FALSE
zhen_30,"Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH. Morbidity and
cost burden of methicillin-resistant Staphylococcus aureus in early onset
ventilator-associated pneumonia. Crit care (London, England). 2006;10:R97.",Staphylococcus aureus,sau,methicillin,RTI,Shorr,2006,01/2002-12/2003,Cohort,USA,59,95,1,AMR,,,median,IQR,20,11,32,,15,11,23,,0.04,,,,,,,1,21,FALSE,FALSE,FALSE
zhen_45,"Song X, Perencevich E, Campos J, Short BL, Singh N. Clinical and economic
impact of methicillin-resistant Staphylococcus aureus colonization or
infection on neonates in intensive care units. Infect Control Hosp Epidemiol.
2010;31:177–82.",Staphylococcus aureus,sau,methicillin,INF,Song,2010,09/2004-03/2008.,Cohort,USA,63,2089,0,DRI,2008,USD,excess,95ci,164301,158712,169889,,,,,,,,,,,,"Neonates in ICU, infection, p<0.001, cost year not explicitly specified ",1,100,FALSE,FALSE,FALSE
zhen_45,"Song X, Perencevich E, Campos J, Short BL, Singh N. Clinical and economic
impact of methicillin-resistant Staphylococcus aureus colonization or
infection on neonates in intensive care units. Infect Control Hosp Epidemiol.
2010;31:177–82.",Staphylococcus aureus,sau,methicillin,INF,Song,2010,09/2004-03/2008.,Cohort,USA,63,2089,1,DRI,,,excess,95ci,40,34.2,45.6,,,,,,,,,,,,"Neonates in ICU, infection, p<0.001",1,100,FALSE,FALSE,FALSE
zhen_45,"Song X, Perencevich E, Campos J, Short BL, Singh N. Clinical and economic
impact of methicillin-resistant Staphylococcus aureus colonization or
infection on neonates in intensive care units. Infect Control Hosp Epidemiol.
2010;31:177–82.",Staphylococcus aureus,sau,methicillin,COL,Song,2010,09/2004-03/2008.,Cohort,USA,128,2089,0,DRI,2008,USD,excess,95ci,51665,48248,55081,,,,,,,,,,,,"Neonates in ICU, infection, p<0.001, cost year not explicitly specified ",1,101,FALSE,FALSE,FALSE
zhen_45,"Song X, Perencevich E, Campos J, Short BL, Singh N. Clinical and economic
impact of methicillin-resistant Staphylococcus aureus colonization or
infection on neonates in intensive care units. Infect Control Hosp Epidemiol.
2010;31:177–82.",Staphylococcus aureus,sau,methicillin,COL,Song,2010,09/2004-03/2008.,Cohort,USA,128,2089,1,DRI,,,excess,95ci,1.059,4.8,13.2,,,,,,,,,,,,"Neonates in ICU, infection, p<0.001",1,101,FALSE,FALSE,FALSE
cassini_169,"Soriano A, Martinez JA, Mensa J, et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Feb 2000;30(2):368-373.",Staphylococcus aureus,sau,methicillin,BSI,Soriano,2001,01/91-12/98,Cohort study,Spain,163,163,1,AMR,,,mean,pvalue,15,,,,11,,,,0.1,,,,,,"pre-existing
comorbidities
, underlying
disease, LOS,
and age",0,0,FALSE,FALSE,FALSE
cassini_197,"Spindel SJ, Strausbaugh LJ, Jacobson C. Infections caused by Staphylococcus aureus in a Veterans' Affairs nursing home care unit: a 5-year experience. Infection control and hospital epidemiology. Apr 1995;16(4):217-223.",Staphylococcus aureus,sau,methicillin,INF,Spindel,1995,01/87-12/91,Observational,USA,20,48,1,AMR,,,mean,pvalue,15,,,,12,,,,0.5,,,,,,gives count breakdown of source,0,0,FALSE,FALSE,FALSE
naylor_188,"Stewardson A, Fankhauser C, De Angelis G, Rohner P, Safran E, Schrenzel J, et al. Burden of bloodstream infection caused by extended-spectrum ?-lactamase-producing enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model. Infection control and hospital epidemiology?: the official journal of the Society of Hospital Epidemiologists of America. 2013;34:133–43. ",Enterobacteriaceae,ent,ESBL,BSI,Stewardson,2013,2009,Cohort,Switzerland,49,49,0,AMR,2009,CHF,excess_median,IQR,24576,14309,47264,,,,,,0.136,,,,,,"median excess, matched on Age, Sex, and Diagnosis-Related Group",1,48,FALSE,FALSE,FALSE
naylor_188,"Stewardson A, Fankhauser C, De Angelis G, Rohner P, Safran E, Schrenzel J, et al. Burden of bloodstream infection caused by extended-spectrum ?-lactamase-producing enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model. Infection control and hospital epidemiology?: the official journal of the Society of Hospital Epidemiologists of America. 2013;34:133–43. ",Enterobacteriaceae,ent,ESBL,BSI,Stewardson,2013,2009,Cohort,Switzerland,49,49,1,AMR,,,excess_median,IQR,10,5,20,,,,,,0.006,,,,,,"median excess, matched on Age, Sex, and Diagnosis-Related Group",1,48,FALSE,FALSE,FALSE
naylor_188,"Stewardson A, Fankhauser C, De Angelis G, Rohner P, Safran E, Schrenzel J, et al. Burden of bloodstream infection caused by extended-spectrum ?-lactamase-producing enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model. Infection control and hospital epidemiology?: the official journal of the Society of Hospital Epidemiologists of America. 2013;34:133–43. ",Enterobacteriaceae,ent,ESBL,BSI,Stewardson,2013,2009,Cohort,Switzerland,30,96,1,AMR,,,mean,95ci,9.4,0.4,18.4,,2.6,-0.7,5.9,,,,,,,,multistate model comparing ESBL and non-ESBL to non-infected,0,0,FALSE,FALSE,FALSE
naylor_188,"Stewardson A, Fankhauser C, De Angelis G, Rohner P, Safran E, Schrenzel J, et al. Burden of bloodstream infection caused by extended-spectrum ?-lactamase-producing enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model. Infection control and hospital epidemiology?: the official journal of the Society of Hospital Epidemiologists of America. 2013;34:133–43. ",Enterobacteriaceae,ent,ESBL,BSI,Stewardson,2013,2009,Cohort,Switzerland,30,42476,1,DRI,,,excess,95ci,9.4,0.4,18.4,,,,,,,,,,,,"multistate model on timing of infection, mean excess against non-infected (n=",0,0,FALSE,FALSE,FALSE
cassini_161,"Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study. Eurosurveillance. 2016;21(33).",Enterobacteriaceae,ent,3g cephalosporins,BSI,Stewardson,2016,01/20-12/12,Multicentre retrospective cohort study,Europe,360,2100,1,AMR,,,excess,95ci,3.53,2.08,4.98,,,,,,,,,,,,compared both to non-infected,1,45,FALSE,FALSE,FALSE
wozniak_24,"Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study. Eurosurveillance. 2016;21(33).",Enterobacteriaceae,ent,3g cephalosporins,BSI,Stewardson,2016,01/20-12/12,Multicentre retrospective cohort study,Europe,360,2100,0,AMR,2011,EUR,excess,95ci,3200,1600,6000,,,,,,,,,,,,accounting,1,45,FALSE,FALSE,FALSE
cassini_161,"Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study. Eurosurveillance. 2016;21(33).",Staphylococcus aureus,sau,methicillin,BSI,Stewardson,2016,01/20-12/12,Multicentre retrospective cohort study,Europe,163,885,1,AMR,,,excess,95ci,1.77,-0.51,4.05,,,,,,,,,,,,note compared to non-infected first to then estimate excess values,1,46,FALSE,FALSE,FALSE
wozniak_24,"Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study. Eurosurveillance. 2016;21(33).",Staphylococcus aureus,sau,methicillin,BSI,Stewardson,2016,01/20-12/12,Multicentre retrospective cohort study,Europe,163,885,0,AMR,2011,EUR,excess,95ci,1600,-700,5000,,,,,,,,,,,,accounting,1,46,FALSE,FALSE,FALSE
cassini_161,"Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study. Eurosurveillance. 2016;21(33).",Staphylococcus aureus,sau,methicillin,BSI,Stewardson,2016,01/20-12/12,Multicentre retrospective cohort study,Europe,163,604797,1,DRI,,,excess,95ci,12.22,9.89,14.55,,,,,,,,,,,,note compared to non-infected first to then estimate excess values,0,0,FALSE,FALSE,FALSE
cassini_161,"Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study. Eurosurveillance. 2016;21(33).",Staphylococcus aureus,sau,methicillin,BSI,Stewardson,2016,01/20-12/12,Multicentre retrospective cohort study,Europe,163,604797,0,DRI,2011,EUR,excess,95ci,11000,6600,19000,,,,,,,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_161,"Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study. Eurosurveillance. 2016;21(33).",Enterobacteriaceae,ent,3g cephalosporins,BSI,Stewardson,2016,01/20-12/12,Multicentre retrospective cohort study,Europe,360,603972,1,DRI,,,excess,95ci,7.91,6.66,9.16,,,,,,,,,,,,compared both to non-infected,0,0,FALSE,FALSE,FALSE
cassini_161,"Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study. Eurosurveillance. 2016;21(33).",Enterobacteriaceae,ent,3g cephalosporins,BSI,Stewardson,2016,01/20-12/12,Multicentre retrospective cohort study,Europe,360,603972,0,DRI,2011,EUR,excess,95ci,7300,4300,12000,,,,,,,,,,,,,0,0,FALSE,FALSE,FALSE
wozniak_24,"Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study. Eurosurveillance. 2016;21(33).",Enterobacteriaceae,ent,3g cephalosporins,BSI,Stewardson,2016,01/20-12/12,Multicentre retrospective cohort study,Europe,360,2100,0,AMR,2011,EUR,excess,95ci,250,60,1100,,,,,,,,,,,,opportunity cost,0,0,FALSE,FALSE,FALSE
wozniak_24,"Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study. Eurosurveillance. 2016;21(33).",Staphylococcus aureus,sau,methicillin,BSI,Stewardson,2016,01/20-12/12,Multicentre retrospective cohort study,Europe,163,885,0,AMR,2011,EUR,excess,95ci,120,-60,740,,,,,,,,,,,,opportunity cost,0,0,FALSE,FALSE,FALSE
wozniak_24,"Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study. Eurosurveillance. 2016;21(33).",Enterobacteriaceae,ent,3g cephalosporins,BSI,Stewardson,2016,01/20-12/12,Multicentre retrospective cohort study,Europe,360,2100,0,DRI,2011,EUR,excess,95ci,560,140,2300,,,,,,,,,,,,opportunity cost,0,0,FALSE,FALSE,FALSE
wozniak_24,"Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: A multicentre retrospective cohort study. Eurosurveillance. 2016;21(33).",Staphylococcus aureus,sau,methicillin,BSI,Stewardson,2016,01/20-12/12,Multicentre retrospective cohort study,Europe,163,885,0,DRI,2011,EUR,excess,95ci,890,220,3600,,,,,,,,,,,,opportunity cost,0,0,FALSE,FALSE,FALSE
cassini_322,"Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med. Mar 9 1998;158(5):522-527.",Enterococcus faecium,efa,vancomycin,BSI,Stosor,1998,1992 - 1995,Retrospective comparative,USA,21,32,0,AMR,1995,USD,mean,pvalue,83897,,,,56707,,,,0.04,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_259,"Suarez C, Pena C, Gavalda L, et al. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Sep 2010;14 Suppl 3:e73-78.",Pseudomonas aeruginosa,pae,carbapenems,BSI,Suarez,2010,01/05-12/05,Retrospective cohort study,Spain,33,88,1,AMR,,,mean,range,19,2,98,,9,2,56,,0.03,,,,,,,0,0,FALSE,FALSE,FALSE
founou_61,"Superti SV, Augusti G, Zavascki AP. Risk factors for and mortality of extended-spectrum-beta-lactamase-
producing Klebsiella pneumoniae and Escherichia coli nosocomial bloodstream infections. Rev
Inst Med Trop Sao Paulo. 2009; 51(4):211±6. PMID: 19739001",Enterobacteriaceae,ent,ESBL,BSI,Superti,2009,06/2004-03/2006,Case-control,Thailand,51,94,1,AMR,,,mean,sd,26,,,20,16,,,16,0.002,,,,,,"Nosocomial, adults",0,0,FALSE,FALSE,FALSE
cassini_10,"Tal-Jasper R, Katz DE, Amrami N, et al. Clinical and epidemiological significance of carbapenem resistance in Acinetobacter baumannii infections. Antimicrobial agents and chemotherapy. 2016;60(5):3127-3131.",Acinetobacter baumannii,aba,carbapenems,BSI,Tal-Jasper,2016,01/07-12/12,Retrospective cohort study,Israel,149,91,1,AMR,,,median,IQR,21,10.8,39.5,,10,7,20.5,,,,,,,,,0,0,FALSE,FALSE,FALSE
zhen_29,"Taneja C, Haque N, Oster G, Shorr AF, Zilber S, Kyan PO, et al. Clinical and
economic outcomes in patients with community-acquired Staphylococcus
aureus pneumonia. J Hosp Med. 2010;5:528–34.",Staphylococcus aureus,sau,methicillin,RTI,Taneja,2010,01/2005-05/2008,Cohort,USA,55,73,0,AMR,2008,USD,mean,sd,117489,,,132164,135784,,,170046,0.51,,,,,,"community-associated pneumonia, some information taken from the abstract",0,0,FALSE,FALSE,TRUE
zhen_29,"Taneja C, Haque N, Oster G, Shorr AF, Zilber S, Kyan PO, et al. Clinical and
economic outcomes in patients with community-acquired Staphylococcus
aureus pneumonia. J Hosp Med. 2010;5:528–34.",Staphylococcus aureus,sau,methicillin,RTI,Taneja,2010,01/2005-05/2008,Cohort,USA,55,73,1,AMR,,,mean,sd,18.2,,,16.6,16.4,,,15,0.525,,,,,,,0,0,FALSE,FALSE,FALSE
naylor_196,"Thampi N, Showler A, Burry L, Bai AD, Steinberg M, Ricciuto DR, et al. Multicenter study of health care cost of patients admitted to hospital with Staphylococcus aureus bacteremia: Impact of length of stay and intensity of care. American Journal of Infection Control. Elsevier Inc; 2015;43:739–44. ",Staphylococcus aureus,sau,methicillin,BSI,Thampi,2015,04/07-03/10,Cohort,Canada,58,337,1,AMR,,,median,IQR,22.5,7.5,37.5,,14,9,25,,0.0951,,,,,,>=18 years old,1,22,FALSE,FALSE,FALSE
zhen_40,"Thampi N, Showler A, Burry L, Bai AD, Steinberg M, Ricciuto DR, et al.
Multicenter study of health care cost of patients admitted to hospital with
Staphylococcus aureus bacteremia: impact of length of stay and intensity of
care. Am J Infect Control. 2015;43:739–44.",Staphylococcus aureus,sau,methicillin,BSI,Thampi,2015,04/07-03/10,Cohort,Canada,58,337,0,AMR,2010,CAD,excess,IQR,18711,8994,39863,,11558,6744,27763,,0.0294,,,,,,>=18 years old,1,22,FALSE,FALSE,FALSE
founou_62,"Thatrimontrichai A, Apisarnthanarak A, Chanvitan P, Janjindamai W, Dissaneevate S, Maneenil G.
Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii bacteremia in neonatal
intensive care unit: a case-case-control study. The Pediatric infectious disease journal. 2013; 32
(2):140±5. https://doi.org/10.1097/INF.0b013e318270b108 PMID: 22935872",Acinetobacter baumannii,aba,carbapenems,BSI,Thatrimontrichai,2013,01/1991-12/2010 ,Case-case-control study,Thailand,14,38,1,AMR,,,mean,range,34,2,206,,53.5,3,188,,,,,,,,neonates in ICU,0,0,FALSE,FALSE,TRUE
founou_62,"Thatrimontrichai A, Apisarnthanarak A, Chanvitan P, Janjindamai W, Dissaneevate S, Maneenil G.
Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii bacteremia in neonatal
intensive care unit: a case-case-control study. The Pediatric infectious disease journal. 2013; 32
(2):140±5. https://doi.org/10.1097/INF.0b013e318270b108 PMID: 22935872",Acinetobacter baumannii,aba,carbapenems,BSI,Thatrimontrichai,2013,01/1991-12/2010 ,Case-case-control study,Thailand,14,44,1,DRI,,,median,range,34,2,206,,24.5,1,102,,,,,,,,neonates in ICU,0,0,FALSE,FALSE,FALSE
cassini_11,"Thatrimontrichai A, Techato C, Dissaneevate S, et al. Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: A case-case-control study. Journal of Infection and Chemotherapy. 2016;22(7):444-449.",Acinetobacter baumannii,aba,carbapenems,RTI,Thatrimontrichai,2016,01/09-12/14,Case-case-control study,Thailand,63,13,1,AMR,,,median,range,51,5,287,,42,24,104,,,,,,,,"neonates in ICU, adapted from extraction based on original paper",1,23,FALSE,FALSE,FALSE
cassini_11,"Thatrimontrichai A, Techato C, Dissaneevate S, et al. Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: A case-case-control study. Journal of Infection and Chemotherapy. 2016;22(7):444-449.",Acinetobacter baumannii,aba,carbapenems,RTI,Thatrimontrichai,2016,01/09-12/14,Case-case-control study,Thailand,63,25,1,DRI,,,median,range,51,5,287,,41,16,210,,,,,,,,neonates in ICU,0,0,FALSE,FALSE,FALSE
founou_19,"Thatrimontrichai A, Techato C, Dissaneevate S, Janjindamai W, Gunlawadee M, Supika K, et al. Risk
factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia
in the neonate: A case-case-control study. Journal of Infection and Chemotherapy. 2016; 22(7±
8):444±9.",Acinetobacter baumannii,aba,carbapenems,RTI,Thatrimontrichai,2016,01/09-12/14,Case-case-control study,Thailand,63,13,0,AMR,2014,USD,median,range,11773.3,2174,45618.2,,9735.6,5260.8,24146.2,,,,,,,,,1,23,FALSE,FALSE,FALSE
cassini_11,"Thatrimontrichai A, Techato C, Dissaneevate S, Janjindamai W, Gunlawadee M, Supika K, et al. Risk
factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia
in the neonate: A case-case-control study. Journal of Infection and Chemotherapy. 2016; 22(7±
8):444±9.",Acinetobacter baumannii,aba,carbapenems,RTI,Thatrimontrichai,2016,01/09-12/14,Case-case-control study,Thailand,63,25,0,DRI,2014,USD,median,range,11773.3,2174,45618.2,,7797.9,3873,33574.1,,,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_227,"Theodorou P, Lefering R, Perbix W, et al. Staphylococcus aureus bacteremia after thermal injury: the clinical impact of methicillin resistance. Burns : journal of the International Society for Burn Injuries. May 2013;39(3):404-412.",Staphylococcus aureus,sau,methicillin,BSI,Theodorou,2013,01/89-12/11,Retrospective cohort study,Germany,33,41,1,AMR,,,median,pvalue,28.5,,,,21,,,,0.32,,,,,,burn patients,0,0,FALSE,FALSE,FALSE
cassini_245,"Tosh PK, Bulens SN, Nadle J, et al. Characterization of hospitalized community-onset staphylococcus aureus lower respiratory tract infections among generally healthy persons 50 years of age or younger. Infectious Diseases in Clinical Practice. 2013;21(6):359-365.",Staphylococcus aureus,sau,methicillin,RTI,Tosh,2013,09/08-08/10,Retrospective study,USA,42,52,1,AMR,,,median,pvalue,9,,,,6,,,,0.04,,,,,,all patients had lower respiratory tract infection (LRI),0,0,FALSE,FALSE,FALSE
cassini_69,"Tumbarello M, Spanu T, Di Bidino R, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrobial agents and chemotherapy. Oct 2010;54(10):4085-4091.",Escherichia coli,eco,ESBL,BSI,Tumbarello,2010,01/06-12/06,Retrospective cohort study,Italy,37,97,1,AMR,,,mean,sd,20,,,17,13,,,9,,,,,,,,1,44,FALSE,FALSE,FALSE
zhen_81,"Tumbarello M, Spanu T, Di Bidino R, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrobial agents and chemotherapy. Oct 2010;54(10):4085-4091.",Escherichia coli,eco,ESBL,BSI,Tumbarello,2010,01/06-12/06,Retrospective cohort study,Italy,37,97,0,AMR,2006,USD,mean,sd,13709,,,16312,8683,,,6683,0.03,,,,,,,1,44,FALSE,FALSE,FALSE
cassini_143,"Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrobial agents and chemotherapy. Feb 2006;50(2):498-504.",Klebsiella pneumoniae,kpn,3g cephalosporins,BSI,Tumbarello,2006,01/99-12/03,Case-control study,Italy,48,99,1,AMR,,,mean,sd,34,,,20,31,,,17,,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_260,"Tuon FF, Gortz LW, Rocha JL. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. Jul-Aug 2012;16(4):351-356.",Pseudomonas aeruginosa,pae,carbapenems,BSI,"Tuon",2012,"01/06-01/09","Case-control study",Brazil,29,48,1,AMR,,,mean,sd,43,,,31.7,43.1,,,31.2,0.987,,,,,,,0,0,FALSE,FALSE,TRUE
cassini_152,"Tuon FF, Kruger M, Terreri M, Penteado-Filho SR, Gortz L. Klebsiella ESBL bacteremia-mortality and risk factors. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. Nov-Dec 2011;15(6):594-598.",Klebsiella pneumoniae,kpn,3g cephalosporins,BSI,Tuon,2010,01/06-01/09,Cohort study,Brazil,63,41,1,AMR,,,mean,sd,52.2,,,39.6,36,,,29.4,,,,,,,,0,0,FALSE,FALSE,FALSE
cassini_84,"Van Aken S, Lund N, Ahl J, Odenholt I, Tham J. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia. Scandinavian journal of infectious diseases. Nov 2014;46(11):753-762.",Escherichia coli,eco,3g cephalosporins,BSI,Van Aken,2014,01/11-09/12,Retrospective case-control study,Sweden,70,140,1,AMR,,,median,sd,11,,,12,9,,,10,,,,,,,,0,0,FALSE,FALSE,FALSE
naylor_206,"Vitkauskiene A, Dambrauskiene A, Cerniauskiene K, Rimdeika R, Sakalauskas R. Risk factors and outcomes in patients with carbapenem-resistant Acinetobacter infection. Scandinavian Journal of Infectious Diseases. 2013;45:213–8. ",Acinetobacter baumannii,aba,carbapenems,INF,Vitkauskiene,2013,08/2010-01/2011 ,Cohort,Lithuania,40,59,1,AMR,,,mean,sd,35.63,,,27.44,22.89,,,14.76,0.005,,,,,,"adults, gives count breakdown of source, after infection",0,0,FALSE,FALSE,FALSE
zhen_65,"Webb M, Riley LW, Roberts RB. Cost of hospitalization for and risk factors
associated with vancomycin-resistant Enterococcus faecium infection and
colonization. Clin Infect Dis. 2001;33:445–52.",Enterococcus faecium,efa,vancomycin,COL/INF,Webb,2001,01/1995-12/1996,Case-control,USA,262,157,1,AMR,,,mean,range,48.8,1,390,,34.2,1,501,,,,,,,,"total duration, note also provides  mean cost per person-day of hospitalization but not cost per hospital spell",0,0,FALSE,FALSE,FALSE
naylor_52_refs,"White VL, Moore-Gillon J. Resource implications of patients with multidrug resistant tuberculosis. Thorax 2000;
55: 962–963",Tuberculosis,tb,MDR,RTI,White,2000,1996–1999,Cohort,England,9,18,1,AMR,,,mean,range,77,0,274,,10,0,58,,,,,,,,inpatient days,0,0,FALSE,FALSE,FALSE
naylor_212,"Willmann M, Kuebart I, Marschal M, Schröppel K, Vogel W, Flesch I, et al. Effect of metallo-?-lactamase production and multidrug resistance on clinical outcomes in patients with Pseudomonas aeruginosa bloodstream infection: a retrospective cohort study. BMC Infectious Diseases. 2013;13:515. ",Pseudomonas aeruginosa,pae,MBL,BSI,Willmann,2013,2006-2012,Cohort,Germany,18,95,1,AMR,,,median,IQR,23,20,45,,15,8,41,,0.03,,,,,,adults,0,0,FALSE,FALSE,FALSE
naylor_214,"Wu YH, Chen PL, Hung YP, Ko WC. Risk factors and clinical impact of levofloxacin or cefazolin nonsusceptibility or ESBL production among uropathogens in adults with community-onset urinary tract infections. Journal of Microbiology, Immunology and Infection. Elsevier Taiwan LLC; 2014;47:197–203. ",Enterobacteriaceae,ent,ESBL,UTI,Wu,2014,08/2009-01/2012,Cohort,Taiwan,14,122,1,AMR,,,mean,sd,16.7,,,10.9,9.6,,,7.3,,,,,,,"adults, p <0.01",0,0,FALSE,FALSE,FALSE
cassini_316,"Yoo J-H, Lee, D-G., Choi, SM., Choi, J-H., Shin, W-S., Kim, M., Yong, D., Lee, K., Min, W-S., Kim, C-C. Vancomycin-resistant Enterococcal Bacteremia in a Hematology Unit: Molecular Epidemioogy and Analysis of Clinical Course. Journal of Korean medical science. 2005;20:169-176.",Enterococcus,efa,vancomycin,BSI,Yoo,2005,2000-2001,"Retrospective cohort study",South Korea,19,8,1,AMR,,,mean,sd,22.9,,,13.3,20.7,,,16.7,,,,,,,after bacteraemia,0,0,FALSE,FALSE,FALSE
zhen_99,"zhen X, Chen Y, Hu X, Dong P, Gu S, Sheng YY, et al. The difference in medical costs between carbapenem-resistant Acinetobacter baumannii and non-resistant groups: a case study from a hospital in Zhejiang province, China. Eur J Clin Microbiol Infect Dis. 2017;36:1989–94.",Acinetobacter baumannii,aba,carbapenems,COL/INF,zhen,2017,2013-2015,Retrospective cohort study,China,2126,854,0,AMR,2015,USD,mean,se,30575.14,,,0.37,19783.49,,,0.36,,,,,,,"total inpatient cost, has some % (not 100%) of syndromes for the infections",0,0,FALSE,FALSE,FALSE
cassini_237,"Gimenes M, Salci TP, Tognim MCB, Siqueira VLD, Caparroz-Assef SM. Treating Staphylococcus aureus infections in an intensive care unit at a University Hospital in Brazil. International Journal of Clinical Pharmacy. 2016;38(2):228-232.",Staphylococcus aureus,sau,methicillin,INF,Gimenes,2016,2006-2011,Retrospective study,Brazil,7123,7123,1,AMR,,,median,IQR+,20,,,20,19,,,17,,,,,,,"all patients were in ICU, matched on ICU",0,0,FALSE,FALSE,FALSE
